<SEC-DOCUMENT>0001144204-19-040453.txt : 20190819
<SEC-HEADER>0001144204-19-040453.hdr.sgml : 20190819
<ACCEPTANCE-DATETIME>20190816174420
ACCESSION NUMBER:		0001144204-19-040453
CONFORMED SUBMISSION TYPE:	S-1/A
PUBLIC DOCUMENT COUNT:		3
FILED AS OF DATE:		20190819
DATE AS OF CHANGE:		20190816

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Rezolute, Inc.
		CENTRAL INDEX KEY:			0001509261
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				273440894
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		S-1/A
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-233310
		FILM NUMBER:		191034352

	BUSINESS ADDRESS:	
		STREET 1:		201 REDWOOD SHORES PARKWAY, SUITE 315
		CITY:			REDWOOD CITY
		STATE:			CA
		ZIP:			94065
		BUSINESS PHONE:		650-847-1919

	MAIL ADDRESS:	
		STREET 1:		201 REDWOOD SHORES PARKWAY, SUITE 315
		CITY:			REDWOOD CITY
		STATE:			CA
		ZIP:			94065

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	AntriaBio, Inc.
		DATE OF NAME CHANGE:	20130114

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	FITS MY STYLE INC
		DATE OF NAME CHANGE:	20110104
</SEC-HEADER>
<DOCUMENT>
<TYPE>S-1/A
<SEQUENCE>1
<FILENAME>tv527864_s-1a.htm
<DESCRIPTION>FORM S-1/A
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin-top: 0; text-align: center; margin-bottom: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> As filed with the Securities and Exchange
Commission on August 16, 2019 </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"> File 333-233310 </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;&nbsp;</P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0; margin-bottom: 0; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>UNITED STATES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Washington, D.C. 20549 </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> <B>Pre-Effective</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> <B>Amendment No. 1</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> <B>to</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 2pt 0; text-align: center; border: black 1pt solid"><B>FORM S-1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>REGISTRATION STATEMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>UNDER THE SECURITIES ACT OF 1933</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>REZOLUTE, INC.</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Exact name of registrant as specified in
its charter)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 32%; border-bottom: black 1pt solid; text-align: center"><B>Delaware</B></TD>
    <TD STYLE="width: 2%; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 32%; border-bottom: black 1pt solid; text-align: center"><B>000-54495</B></TD>
    <TD STYLE="width: 2%; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 32%; border-bottom: black 1pt solid; text-align: center"><B>27-3440894</B></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(State or other jurisdiction of<BR>
incorporation)</P></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">(Commission file number)</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(</B>IRS Employer Identification<BR>
No.)</P></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>201 Redwood Shores Parkway, Suite 315</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Redwood City, CA 94065 </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>(650) 206-4507</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Address, including zip code, and telephone
number, including area code of registrant&rsquo;s principal executive offices)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Rezolute, Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Attn: Nevan Elam, CEO</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>201 Redwood Shores Parkway, Suite 315</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Redwood City, CA 94065</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>(650) 206-4507 </U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">(Name, address,
including zip code, and telephone number, including area code, of agent for service)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Copies of communications to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Dorsey &amp; Whitney LLP</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Attn: Michael L. Weiner &amp; Anthony
W. Epps</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>1400 Wewetta Street, Suite 400</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Denver, CO 80202</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>(303) 629-3400</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Approximate date of commencement of
proposed sale to the public: </B>From time to time after the effective date of this registration statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If any of the securities being registered
on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933 check the
following box. <FONT STYLE="font-family: Wingdings"><FONT STYLE="font-family: Wingdings">&#120;</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If this Form is filed to register additional
securities for an offering pursuant to Rule 462(b) under the Securities Act, please check the following box and list the Securities
Act registration statement number of the earlier effective registration statement for the same offering. <FONT STYLE="font-family: Wingdings"></FONT><FONT STYLE="font-family: Wingdings">&#168;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If this Form is a post-effective amendment
filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement
number of the earlier effective registration statement for the same offering. <FONT STYLE="font-family: Wingdings"><FONT STYLE="font-family: Wingdings">&#168;</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If this Form is a post-effective amendment
filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the Securities Act registration statement
number of the earlier effective registration statement for the same offering. <FONT STYLE="font-family: Wingdings"><FONT STYLE="font-family: Wingdings">&#168;</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark whether the Registrant
is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth
company. See the definitions of &ldquo;large accelerated filer,&rdquo; &ldquo;accelerated filer&rdquo;, &ldquo;smaller reporting
company&rdquo; and &ldquo;emerging growth company&rdquo; in Rule 12b-2 of the Exchange Act. (Check one):</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; text-align: center">Large accelerated filer&nbsp;&nbsp;<FONT STYLE="font-family: Wingdings"><FONT STYLE="font-family: Wingdings">&#168;</FONT></FONT></TD>
    <TD STYLE="width: 50%; text-align: center">Accelerated filer&nbsp;&nbsp;<FONT STYLE="font-family: Wingdings"><FONT STYLE="font-family: Wingdings">&#168;</FONT></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">Non-accelerated filer&nbsp;&nbsp;<FONT STYLE="font-family: Wingdings"><FONT STYLE="font-family: Wingdings">&#120;</FONT></FONT></TD>
    <TD STYLE="text-align: center">Smaller&nbsp;reporting&nbsp;company&nbsp;<FONT STYLE="font-family: Wingdings"><FONT STYLE="font-family: Wingdings">&#120;</FONT></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: center">Emerging Growth Company&nbsp;&nbsp;<FONT STYLE="font-family: Wingdings"><FONT STYLE="font-family: Wingdings">&#168;</FONT></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If an emerging growth company, indicate
by check mark if the Registrant has elected not to use the extended transition period for complying with any new or revised financial
accounting standards provided pursuant to Section 17(a)(2)(B) of the Securities Act. <FONT STYLE="font-family: Wingdings">&#168;</FONT><FONT STYLE="font-family: Wingdings"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Calculation of Registration Fee</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center"> Title of Each Class of Securities to be Registered </TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center"> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Amount
    to be&nbsp;&nbsp;<BR>
    Registered <SUP>(1)</SUP></B></FONT> </TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"> &nbsp; </TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center"> Proposed <BR>
    Maximum <BR>
    Offering Price <BR>
    Per Share </TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"> &nbsp; </TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center"> Proposed <BR>
    Maximum <BR>
    aggregate <BR>
    offering price </TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"> &nbsp; </TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: center"> Amount of <BR>
    Registration Fee </TD><TD STYLE="font: bold 10pt Times New Roman, Times, Serif"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt"> &nbsp; </TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt"> &nbsp; </TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt"> &nbsp; </TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt"> &nbsp; </TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt"> &nbsp; </TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt"> &nbsp; </TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt"> &nbsp; </TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="font-size: 10pt"> &nbsp; </TD><TD STYLE="padding-bottom: 1pt; font-size: 10pt"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 36%; font: 10pt Times New Roman, Times, Serif"> Common stock, par value $0.001 </TD><TD STYLE="width: 2%; font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="width: 12%; font: 10pt Times New Roman, Times, Serif; text-align: right"> 231,454,572 </TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"> <SUP>(2)</SUP> </TD><TD STYLE="width: 2%; font-size: 10pt"> &nbsp; </TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left"> $ </TD><TD STYLE="width: 12%; font-size: 10pt; text-align: right"> 0.21 </TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left"> <SUP>(3)</SUP> </TD><TD STYLE="width: 2%; font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"> $ </TD><TD STYLE="width: 12%; font: 10pt Times New Roman, Times, Serif; text-align: right"> 48,605,460.12 </TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD><TD STYLE="width: 2%; font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"> $ </TD><TD STYLE="width: 12%; font: 10pt Times New Roman, Times, Serif; text-align: right"> 5,890.98 </TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left"> <SUP>(4)</SUP> </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> Total Registration Fee </TD><TD STYLE="font-size: 10pt"> &nbsp; </TD>
    <TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt; text-align: right"> &nbsp; </TD><TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt"> &nbsp; </TD>
    <TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt; text-align: right"> &nbsp; </TD><TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt"> &nbsp; </TD>
    <TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt; text-align: right"> &nbsp; </TD><TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> $ </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right"> 5,890.98 </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> &nbsp; </TD></TR>
</TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>





<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(1)</TD><TD STYLE="text-align: justify">Pursuant to Rule 416 under the Securities Act of 1933, as amended (the &ldquo;<B>Securities Act</B>&rdquo;),
the shares of common stock being registered hereunder also include an indeterminate number of additional shares of common stock
as may become issuable as a result of stock splits, stock dividends, stock distributions and similar transactions.</TD></TR>                                                                                                                            <TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
</TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(2)</TD><TD STYLE="text-align: justify">Represents 231,454,572 shares of common stock, par value $0.001 per share, issued upon, (A) the
conversion of the Company&rsquo;s Series AA Preferred Stock previously issued to the Selling Stockholders named herein in either,
(i) the Series AA Financing or (ii) the conversion of certain outstanding senior secured promissory notes at the closing of the
Series AA Financing and (B) the completion of the Company&rsquo;s 2019 common stock offering.</TD></TR>                                                                                                       <TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
</TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(3)</TD><TD STYLE="text-align: justify">Estimated solely for the purpose of calculating the registration fee pursuant to Rule 457(c)
                                                                 under the Securities using the average of the high and low prices of the common stock on the OTCQB on August 14, 2019.</TD></TR>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   <TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD> &nbsp; </TD><TD> (4) </TD><TD STYLE="text-align: justify"> Previously paid. </TD></TR>
</TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>This registrant hereby amends this Registration
Statement on such date or dates as may be necessary to delay its effective date until the registrant shall file a further amendment
which specifically states that this Registration Statement shall thereafter become effective in accordance with section 8(a) of
the Securities Act of 1933 or until the Registration Statement shall become effective on such date as the commission, acting pursuant
to section 8(a) may determine. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0; margin-bottom: 0; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>The information in this prospectus is
not complete and may be changed. Our Selling Stockholders may not sell these securities until the registration statement filed
with the U.S. Securities and Exchange Commission is effective. This prospectus is not an offer to sell these securities and is
not soliciting an offer to buy these securities in any state where the offer or sale is not permitted.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"> <B>SUBJECT TO COMPLETION, DATED AUGUST
16, 2019</B> </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>REZOLUTE INC.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PRELIMINARY PROSPECTUS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><IMG SRC="img001.jpg" ALT="" STYLE="height: 52px; width: 259px"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">231,454,572 Shares of Common Stock</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This prospectus relates to the offer and
sale of up to 231,454,572 shares of common stock, par value $0.001, of Rezolute, Inc., a Delaware based corporation, by the selling
stockholders named herein (the &ldquo;<B>Selling Stockholders</B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The shares of common stock being offered
by the Selling Stockholders have been issued pursuant to, (A) the conversion of our Series AA Purchase issued to the Selling Stockholders
in either, (i) the Series AA Financing or (ii) the conversion of certain outstanding senior secured promissory notes into shares
of Series AA Preferred Stock at the closing of the Series AA Financing and (B) our 2019 Private Placement of common stock. We are not offering
or selling any securities under this prospectus and will not receive any of the proceeds from the sale of shares by the Selling
Stockholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Selling Stockholders may sell the shares
of common stock described in this prospectus in a number of different ways and at varying prices. See &ldquo;Plan of Distribution&rdquo;
for more information about how the Selling Stockholders may sell the shares of common stock being registered pursuant to this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our common stock is listed on OTCQB under
the symbol &ldquo;RZLT&rdquo;. On August 14, 2019, the last reported sale price of our common stock on OTCQB was $0.20.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>You should consider carefully the risks
that we have described in the section entitled &ldquo;Risk Factors&rdquo; beginning on Page 5 of this prospectus before
deciding whether to invest in our common stock. </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Neither the U.S. Securities and Exchange
Commission nor any state securities commission has approved or disapproved of these securities or determined if this prospectus
is truthful or complete. Any representation to the contrary is a criminal offense.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>The date of this prospectus is ___________,
2019</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B></B></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">TABLE OF CONTENTS</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>



<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 90%; text-align: left; text-indent: -0.5in; padding-top: 0in; padding-bottom: 0pt; padding-left: 0.5in"></TD>
    <TD STYLE="width: 10%; text-align: right; padding-top: 0in; padding-bottom: 0pt"></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; text-indent: -0.5in; padding-top: 0in; padding-bottom: 0pt; padding-left: 0.5in">&nbsp;</TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 0pt"><B>Page</B></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; text-indent: -0.5in; padding-top: 0in; padding-bottom: 0pt; padding-left: 0.5in">&nbsp;</TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 0pt">&nbsp;</TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.5in; padding-top: 0in; padding-bottom: 0pt; padding-left: 0.5in"><A HREF="#Abouttheprospectus">ABOUT THE PROSPECTUS</A></TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 0pt"><A HREF="#Abouttheprospectus">1</A></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.5in; padding-top: 0in; padding-bottom: 0pt; padding-left: 0.5in"><A HREF="#Specialnoteregarding">SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS</A></TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 0pt"><A HREF="#Specialnoteregarding">1</A></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.5in; padding-top: 0in; padding-bottom: 0pt; padding-left: 0.5in"><A HREF="#Prospectussummary">PROSPECTUS SUMMARY</A></TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 0pt"><A HREF="#Prospectussummary">2</A></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.5in; padding-top: 0in; padding-bottom: 0pt; padding-left: 0.5in"><A HREF="#RISKFACTORS">RISK FACTORS</A></TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 0pt"><A HREF="#RISKFACTORS">5</A></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.5in; padding-top: 0in; padding-bottom: 0pt; padding-left: 0.5in"><A HREF="#THEFINANCINGS">THE
    FINANCINGS</A></TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 0pt"><A HREF="#THEFINANCINGS">5</A></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.5in; padding-top: 0in; padding-bottom: 0pt; padding-left: 0.5in"><A HREF="#USEOFPROCEEDS">USE OF PROCEEDS</A></TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 0pt"><A HREF="#USEOFPROCEEDS">5</A></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.5in; padding-top: 0in; padding-bottom: 0pt; padding-left: 0.5in"><A HREF="#DESCRIPTIONOFCAPITALSTOCK">DESCRIPTION OF CAPITAL STOCK</A></TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 0pt"><A HREF="#DESCRIPTIONOFCAPITALSTOCK">6</A></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.5in; padding-top: 0in; padding-bottom: 0pt; padding-left: 0.5in"><A HREF="#SELLINGSTOCKHOLDERS">SELLING STOCKHOLDERS</A></TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 0pt"><A HREF="#SELLINGSTOCKHOLDERS">6</A></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.5in; padding-top: 0in; padding-bottom: 0pt; padding-left: 0.5in"><A HREF="#PLANOFDISTRIBUTION">PLAN OF DISTRIBUTION</A></TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 0pt"><A HREF="#PLANOFDISTRIBUTION">10</A></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.5in; padding-top: 0in; padding-bottom: 0pt; padding-left: 0.5in"><A HREF="#LEGALMATTERS">LEGAL MATTERS</A></TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 0pt"><A HREF="#LEGALMATTERS">12</A></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.5in; padding-top: 0in; padding-bottom: 0pt; padding-left: 0.5in"><A HREF="#EXPERTS">EXPERTS</A></TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 0pt"><A HREF="#EXPERTS">12</A></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.5in; padding-top: 0in; padding-bottom: 0pt; padding-left: 0.5in"><A HREF="#WHEREYOUCANFINDADDITIONALINFORMATION">WHERE YOU CAN FIND ADDITIONAL INFORMATION</A></TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 0pt"><A HREF="#WHEREYOUCANFINDADDITIONALINFORMATION">12</A></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.5in; padding-top: 0in; padding-bottom: 0pt; padding-left: 0.5in"><A HREF="#DOCUMENTSINCORPORATEDBYREFERENCE">DOCUMENTS INCORPORATED BY REFERENCE</A></TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 0pt"><A HREF="#DOCUMENTSINCORPORATEDBYREFERENCE">12</A></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.5in; padding-top: 0in; padding-bottom: 0pt; padding-left: 0.5in"><A HREF="#PARTII">PART II &ndash; INFORMATION NOT REQUIRED IN PROSPECTUS</A></TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 0pt"><A HREF="#PARTII">II-1</A></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; text-indent: -0.5in; padding-top: 0in; padding-bottom: 0pt; padding-left: 0.5in"><A HREF="#signature">SIGNATURES</A></TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 0pt"><A HREF="#signature">18</A></TD></TR>
<TR STYLE="text-align: left; vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="text-align: left; text-indent: -0.5in; padding-top: 0in; padding-bottom: 0pt; padding-left: 0.5in"><A HREF="#Exhibiindex">EXHIBIT INDEX</A></TD>
    <TD STYLE="text-align: right; padding-top: 0in; padding-bottom: 0pt"><A HREF="#Exhibiindex">19</A></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B><I>You may only rely on the information
contained in this prospectus or that we have referred you to. We have not authorized anyone to provide you with different information.
This prospectus does not constitute an offer to sell or a solicitation of an offer to buy any securities other than the common
stock offered by this prospectus. This prospectus does not constitute an offer to sell or a solicitation of an offer to buy any
common stock in any circumstances in which such offer or solicitation is unlawful. Neither the delivery of this prospectus nor
any sale made in connection with this prospectus shall, under any circumstances, create any implication that there has been no
change in our affairs since the date of this prospectus or that this prospectus is correct as of any time after its date.</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;<B><I>&nbsp;&nbsp;&nbsp;</I></B></P>

<!-- Field: Page; Sequence: 3; Options: NewSection -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">i</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><A NAME="Abouttheprospectus"></A>ABOUT THE PROSPECTUS</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In this prospectus, references to the &ldquo;<B>Company</B>,&rdquo;
&ldquo;<B>Rezolute</B>,&rdquo; &ldquo;<B>we</B>,&rdquo; &ldquo;<B>us</B>,&rdquo; &ldquo;<B>our</B>&rdquo; and similar terms refer
to Rezolute, Inc. References to our &ldquo;common stock&rdquo; refer to the common stock, par value $0.001 per share, of Rezolute,
Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">You should read this prospectus together
with information incorporated herein by reference as described under the heading &ldquo;Documents Incorporated by Reference&rdquo;
and the additional information described under the headings &ldquo;Where You Can Find More Information.&rdquo; If there is any
inconsistency between the information in this prospectus and the documents incorporated by reference herein, you should rely on
the information in this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">You should rely only on the information
contained in or incorporated by reference in this prospectus. We have not authorized any other person to provide information different
from that contained in this prospectus and the documents incorporated by reference herein. If anyone provides you with different
or inconsistent information, you should not rely on it. You should assume that the information appearing in this prospectus is
accurate as of the dates on the cover page, regardless of time of delivery of the prospectus or any sale of securities. Our business,
financial condition, results of operation and prospects may have changed since those dates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><A NAME="Specialnoteregarding"></A>SPECIAL NOTE REGARDING
FORWARD-LOOKING STATEMENTS</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Information set forth in this prospectus
and the information it incorporates by reference may contain various &ldquo;forward-looking statements&rdquo; within the meaning
of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act of 1934, as amended (the &ldquo;<B>Exchange
Act</B>&rdquo;). All information relative to future markets for our products and trends in and anticipated levels of revenue, gross
margins and expenses, as well as other statements containing words such as &ldquo;believe,&rdquo; &ldquo;project,&rdquo; &ldquo;may,&rdquo;
&ldquo;will,&rdquo; &ldquo;anticipate,&rdquo; &ldquo;target,&rdquo; &ldquo;plan,&rdquo; &ldquo;estimate,&rdquo; &ldquo;expect&rdquo;
and &ldquo;intend&rdquo; and other similar expressions constitute forward-looking statements. These forward-looking statements
are subject to business, economic and other risks and uncertainties, both known and unknown, and actual results may differ materially
from those contained in the forward-looking statements. Examples of risks and uncertainties that could cause actual results to
differ materially from historical performance and any forward-looking statements include, but are not limited to, the risks described
under the heading &ldquo;Risk Factors&rdquo; beginning on page 11 of this prospectus, in our most recent Annual Report on Form
10-K, as well as any subsequent filings with the United States Securities and Exchange Commission (the &ldquo;<B>SEC</B>&rdquo;).
Given these risks, uncertainties and other factors, you should not place undue reliance on these forward-looking statements. Also,
these forward-looking statements represent our estimates and assumptions only as of the date such forward-looking statements are
made. You should read carefully this prospectus and any related free writing prospectuses that we have authorized for use in connection
with this offering, together with the information incorporated herein or therein by reference as described under the heading &ldquo;Where
You Can Find More Information,&rdquo; completely and with the understanding that our actual future results may be materially different
from what we expect. We hereby qualify all of our forward-looking statements by these cautionary statements. Except as required
by law, we assume no obligation to update these forward-looking statements publicly or to update the reasons actual results could
differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the
future.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;&nbsp;&nbsp;</P>

<!-- Field: Page; Sequence: 4; Options: NewSection -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<DIV STYLE="border: Black 1pt solid; padding: 5pt">

<P STYLE="font: 5pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><A NAME="Prospectussummary"></A>PROSPECTUS SUMMARY</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><I>This summary highlights selected information
about Rezolute, Inc. and a general description of the securities that may be offered for resale or other disposition by the Selling
Stockholders. This summary is not complete and does not contain all of the information that may be important to you. For a more
complete understanding of us and the securities offered by the Selling Stockholders, you should carefully read this entire prospectus,
including the &ldquo;Risk Factors&rdquo; section, any applicable prospectus supplement for these securities and the other documents
we refer to and incorporate by reference. In particular, we incorporate important business and financial information into this
prospectus by reference.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">REZOLUTE, INC.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in; text-align: justify"><FONT STYLE="font-weight: normal">Rezolute
is a clinical stage biotechnology company developing transformative therapies targeting rare and metabolic diseases. These therapies
utilize well-known genetic pathways and mechanisms of action.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Our Pipeline</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><IMG SRC="img002.jpg" ALT="A screenshot of a cell phone&#10;&#10;Description automatically generated" STYLE="height: 198px; width: 577px"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in">RZ358</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Congenital Hyperinsulinism (&ldquo;<B>CHI</B>&rdquo;)
is a rare genetic disorder that affects 1 in 50,000 to 1 in 30,000 newborns. In areas of high consanguinity, the incidence may
increase to 1 in 2,500 newborns.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">CHI can be caused by one of more than ten
known genetic mutations. These mutations may occur within the beta cells of the pancreas and lead to excessive insulin secretion.
The most common mutations occur at the ABCC8 and KCNJ11 genes that encode the SUR-1 and Kir6.2 subunits of the KATP channel.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Ordinarily, beta cells in the pancreas secrete
just enough insulin to keep blood sugar in the normal range. With CHI, the secretion of insulin is not properly regulated. The
beta cells secrete too much insulin. This results in excessively low blood sugar or severe hypoglycemia.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">CHI is the most common cause of persistent
hypoglycemia in infants and children. Persistent hypoglycemia increases risks of long-term neurologic complications. Episodes are
characterized by lethargy, irritability, and / or difficulty feeding. Repeated episodes of hypoglycemia increase the risk of serious
complications such as breathing difficulties, developmental delays, intellectual disability, vision loss, brain damage, seizures,
coma, and possibly death.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We believe that existing management options
are suboptimal. To start, no medical therapy has been developed and approved for CHI. To avoid hypoglycemia, many children require
frequent glucose monitoring and feeding, including intravenous or intestinal administration of sugar solutions, particularly overnight.
Due to genetics or other factors, medical therapies currently used in practice do not adequately treat a significant number of
children and / or have side effects not well tolerated. Surgical removal of all or part of the pancreas may be an option, but is
invasive and often diabetes-inducing. All in all, current treatment regimens are often ineffective, burdensome, and / or have a
substantially negative effect on the quality of life for these children and their families.</P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<DIV STYLE="padding: 5pt; border: Black 1pt solid">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We believe that RZ358 is a first-in-class,
fully human, monoclonal antibody specifically designed, among other potential indications, as a universal treatment for all forms
of CHI. The unique, reversible mechanism of action binds with high affinity to the insulin receptor at the allosteric site. This
action makes it ideally suited as a potential therapy for conditions associated with endogenous hyperinsulinism, such as CHI. This
binding is also highly selective with no IGF-1 interaction. In the setting of elevated insulin, RZ358 dims the insulin signal,
while still allowing insulin to bind and signal. This occurs downstream from the beta-cells, where genetic mutations leading to
hyperinsulinism occur. RZ358 was designed as, and Rezolute is developing as, among other potential indications, a universal treatment
for all forms of CHI.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">RZ358 has been in several clinical studies,
including two Phase 1 and three Phase 2. Subjects have included children, adults, healthy folks, and patients. Phase 2a studies
have demonstrated clinical proof-of-concept in CHI.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Rezolute is currently launching a Phase 2b
study in CHI and anticipates dosing the first patient later this year.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">RZ358 has designated orphan status in the
US and EU.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in"><I>RZ402</I></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Diabetic Macular Edema (&ldquo;<B>DME</B>&rdquo;)
is one of the main causes of vision loss in working-age adults globally. With the growth of diabetes, prevalence in the US is
estimated to increase beyond the current estimate of 750,000 individuals.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">DME is a metabolic disease that results from
an increase in retinal vascular permeability (RVP) in the setting of diabetic retinopathy (abnormal retinal blood vessel growth
caused by poorly controlled blood sugar levels). Vascular leakage from retinal blood vessels leads to swelling of the retina, including
the macula, an area of the retina that is very important for vision. The kinin system and the production of bradykinin have been
implicated in the vascular leakage associated with DME.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">While the market is very large, current treatment
approaches are onerous. They involve injections into the eye by retinal specialists on a monthly or bimonthly basis. In addition
to a segment of the DME population that does not respond to these treatments, the extent of therapeutic benefit directly correlates
with adherence to this route of administration. As the regimen is a significant burden for both patients and their healthcare providers,
high rates of non-adherence and ultimately, suboptimal therapeutic outcomes exist.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">RZ402 is a potential new therapy for DME.
RZ402 has been shown to normalize RVP in clinically-relevant animal models of macular edema as effectively as the current injectable
treatments with exposure-response studies supporting once daily dosing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Rezolute plans to file an IND for RZ402 in
mid 2020.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in">AB101</P>

<P STYLE="font: italic bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The basal insulin market is estimated to exceed
$20 billion annually and has need of therapies with duration of action longer than daily.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">AB101 is a microsphere formulation of PEGylated
human recombinant insulin. It is being developed as an extended acting basal insulin intended for once-weekly subcutaneous injection,
for use alone and in combination with bolus prandial insulin or oral glucose lowering therapies, to improve glycemic control in
patients with Type&nbsp;1 and Type&nbsp;2 Diabetes Mellitus. We believe AB101 has the potential to provide a near peak-less, slow
and uniform release of basal insulin.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Rezolute is currently conducting a Phase 1
study in Type 1 Diabetes Mellitus and anticipates top line results later this year. Following analyses of this data, we will evaluate
out-licensing potential.</P>

</DIV>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Corporate Information</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our principal executive offices are located
at 201 Redwood Shores Parkway, Suite 315 Redwood City, CA 94065, and our telephone number is (650) 206-4507. Our internet address
is http://www.rezolutebio.com. The information on our website is not incorporated by reference into this prospectus, and you should
not consider it part of this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">The Offering</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 49%; text-align: justify">Common stock offered by the Selling Shareholders</TD>
    <TD STYLE="width: 2%; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 49%; text-align: justify">231,454,572 shares of common stock.</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">Common stock outstanding prior to this offering</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">293,320,891<SUP>(1)</SUP></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">Use of Proceeds</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">We will receive no proceeds from the sale of shares of common stock by the Selling Stockholders</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">OTCQB symbol for our Common Stock</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&ldquo;RZLT&rdquo;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">Risk Factors</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">This investment involves a high degree of risk. See &ldquo;Risk Factors&rdquo; in this prospectus and in the documents incorporated by reference in this prospectus, including the risk factors described under the section entitled &ldquo;Risk Factors&rdquo; contained in our Annual Report on Form&nbsp;10-K for the year ended June 30, 2018 for a discussion of factors you should consider carefully before making an investment decision.</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left">(1)</TD><TD STYLE="text-align: justify">Excludes:</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">*</TD><TD STYLE="text-align: justify">45,997,391 warrants issued and outstanding</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"> * </TD><TD STYLE="text-align: justify"> 13,865,417
                                         stock options granted and outstanding (excludes options granted on July 31, 2019). </TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<!-- Field: Page; Sequence: 7 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; text-align: center; margin-bottom: 0pt"><B></B></P>

<!-- Field: Split-Segment; Name: 1 -->
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><A NAME="RISKFACTORS"></A>RISK FACTORS</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Investing in shares of our common stock
involves significant risks. Please see the risk factors under the heading &ldquo;Risk Factors&rdquo; in our most recent Annual
Report on Form 10-K, as revised or supplemented by our Quarterly Reports on Form 10-Q filed with the SEC since the filing of our
most recent Annual Report on Form 10-K, each of which are on file with the SEC and are incorporated by reference in this prospectus.
Before making an investment decision, you should carefully consider these risks as well as other information we include or incorporate
by reference in this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><A NAME="THEFINANCINGS"></A>THE FINANCINGS</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Series AA Financing</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As disclosed in our Current Report on Form
8-K filed with the SEC, on January 7, 2019, we entered into the Purchase Agreement with Handok, Inc. and Genexine, Inc. whereby
subject to certain closing conditions, the Purchasers agreed to purchase Series AA Preferred Stock for aggregate gross proceeds
to the Company of $25,000,000 (each Purchaser paid $12,500,000 to the Company). The Series AA Preferred Stock had an effective
conversion price of $0.22 per share of common stock. On January 30, 2019, we closed the Series AA Financing and issued 1,250,000
Series AA Preferred to each Purchaser pursuant to Section 4(a)(2) of the Securities Act at a purchase price of $10.00 per share
of Series AA Preferred Stock. In addition, because the Series AA Financing qualified as a qualified financing under certain of
our outstanding senior secured notes, the outstanding principal and interest due thereunder was automatically converted into the
Series AA Preferred Stock at a 20% discount. As a result of the closing of the Series AA Financing, the notes plus accrued interest
of $800,117 were automatically converted into 767,515 shares of Series AA Preferred Stock. The Series AA Preferred Stock was issued
to the note holders pursuant to Section 4(a)(2) of the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As a result of the issuance of the Series
AA Preferred Stock to the Purchasers, a change in control of the Company has occurred since the Purchasers collectively own 54%
(each owning approximately 27% of our common stock on an as-converted basis) of our common stock on an as-converted basis. Each
Purchaser used their working capital as a source of funds to purchase their respective portion of the Series AA Preferred Stock
offered in the Series AA Financing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On April 24, 2019, our stockholders approved
an amendment to our Certificate of Incorporation to increase the authorized shares of common stock to 500,000,000. On April 26,
2019, we filed an amendment to the Certificate with the Delaware Secretary of State to effect the share increase. As a result,
the shares of Series AA Preferred Stock were automatically converted into 148,523,540 shares of common stock offered for resale
by the Selling Stockholders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Private Placement of Common Stock</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As disclosed in our Current Report on
Form 8-K filed with the SEC, on July 30, 2019, we entered into a Purchase Agreement with Handok, Inc., Genexine, Inc. and
certain other accredited investors (collectively, the &ldquo;<B>Investors</B>&rdquo;), whereby subject to certain closing
conditions, the Investors agreed to purchase 69,827,584 shares of our common stock at a price per share of $0.29 for
aggregate gross proceeds of $20,250,000. The shares of common stock were issued pursuant to Section 4(a)(2) of the Securities
Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As disclosed in our Current Report on Form 8-K filed with the
SEC, on August 13, 2019, we entered into a Purchase Agreement with another accredited investor (collectively, the &ldquo;<B>Investors</B>&rdquo;),
whereby subject to certain closing conditions, the Investors agreed to purchase 13,103,448 shares of our common stock at a price
per share of $0.29 for aggregate gross proceeds of $3,800,000. The shares of common stock were issued pursuant to Section 4(a)(2)
of the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><A NAME="USEOFPROCEEDS"></A>USE OF PROCEEDS</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We will not receive any proceeds from the
sale of the shares of our common stock by the Selling Stockholders from time to time pursuant to this prospectus. The proceeds
from the offering are solely for the account of the selling stockholders. See &ldquo;Selling Stockholders.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 1; Options: NewSection; Value: 5 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><A NAME="DESCRIPTIONOFCAPITALSTOCK"></A>DESCRIPTION OF CAPITAL
STOCK</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our authorized capital stock consists of
293,320,891 shares of common stock, $0.001 par value per share, and 20,000,000 shares of preferred stock in one or more series,
$0.001 par value per share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Common Stock</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of August 13, 2019, there were
293,320,891 shares of our common stock outstanding held of record by approximately 380 stockholders. In addition, there are
outstanding options, warrants and rights to acquire additional shares of common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Holders of the common stock are entitled
to one vote per share on all matters submitted to the stockholders for a vote. There are no cumulative voting rights in the election
of directors. The shares of common stock are entitled to receive such dividends as may be declared and paid by the Board of Directors
out of funds legally available therefor and to share, ratably, in the net assets, if any, of Rezolute upon liquidation. The stockholders
have no preemptive rights to purchase any shares of our capital stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The transfer agent for the common stock
is VStock, Cedarhurst, New York. Our common stock is traded on the OTCQB and is quoted under the symbol &ldquo;RZLT.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Preferred Stock</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our certificate of incorporation authorizes
20,000,000 shares of preferred stock. Our Board is authorized, without further stockholder action, to establish various series
of preferred stock from time to time and to determine the rights, preferences and privileges of any unissued series including,
among other matters, any dividend rights, dividend rates, conversion rights, voting rights, terms of redemption, liquidation preferences,
sinking fund terms, the number of shares constituting any such series, and the description thereof and to issue any such shares.
There are no issued and outstanding shares of Preferred Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><A NAME="SELLINGSTOCKHOLDERS"></A>SELLING STOCKHOLDERS</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">This prospectus covers
the offer and sale by the Selling Stockholders identified below of 231,454,572 shares of our common stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">We are registering the
shares of common stock in order to permit the Selling Stockholders to offer the shares of common stock for resale from time to
time. The registration of such common stock does not necessarily mean, however, that any of the shares of common stock will be
offered or sold by the Selling Stockholders. We will not receive any proceeds from the sale of the common stock by the Selling
Stockholders, and we have borne and will continue to bear the costs relating to the registration of these shares of common stock,
other than commissions and discounts of agents or broker-dealers and transfer taxes, if any.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">Except as disclosed in
the footnotes below and except for the beneficial ownership of the common stock described in the table below, none of the Selling
Stockholders has held any position or office or had any other material relationship with us or any of our predecessors or affiliates
within the past three years. Except as disclosed in the footnotes below, no Selling Stockholder had a material relationship with
the Company or any of its affiliates within the last three years.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">The following table and
the accompanying footnotes are based in part on information supplied to us by the Selling Stockholders. The table and footnotes
assume that the Selling Stockholders will sell all of the shares listed. However, because the Selling Stockholders may sell none
of their shares or sell all or some of their shares under this prospectus from time to time, or in another permitted manner, we
cannot assure you as to the actual number of shares that will be sold by the Selling Stockholders or that will be held by the Selling
Stockholders after completion of any sales. We do not know how long the Selling Stockholders will hold the shares before selling
them.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">Beneficial ownership
has been determined under rules promulgated by the SEC. The information does not necessarily indicate beneficial ownership for
any other purpose. Under the rules of the SEC, a person is deemed to be a &ldquo;beneficial owner&rdquo; of a security if that
person has or shares &ldquo;voting power,&rdquo; which includes the power to vote or to direct the voting of such security, or
&ldquo;investment power,&rdquo; which includes the power to dispose of or to direct the disposition of such security. Shares of
common stock subject to options currently exercisable and convertible securities currently convertible, or exercisable or convertible
within 60 days after the date of this prospectus, are deemed outstanding for purposes of computing the percentage beneficially
owned by the person or entity holding such securities but are not deemed outstanding for purposes of computing the percentage beneficially
owned by any other person or entity. The inclusion of any shares in this table does not constitute an admission of beneficial ownership
by the persons named below. Please carefully read the footnotes located below the table in conjunction with the information presented
in the table.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 2; Value: 5 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; border-bottom: Black 1pt solid"> Name of Selling Stockholders </TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt"> &nbsp; </TD>
    <TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid"> Number
    of Shares Owned Before the Offering </TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid"> Number
    of Shares Being Offered </TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid"> Number
    of Shares Owned After the Offering (2) </TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt"> &nbsp; </TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; border-bottom: Black 1pt solid"> Percentage
    of Shares Owned After the Offering (1) (2) </TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 42%; font: 10pt Times New Roman, Times, Serif; text-align: left"> Genexine, Inc. </TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD STYLE="width: 5%; font: 10pt Times New Roman, Times, Serif; text-align: left"> (3) </TD><TD STYLE="width: 1%; font-size: 10pt"> &nbsp; </TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right"> 91,300,933 </TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="width: 1%; font-size: 10pt"> &nbsp; </TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right"> 91,300,933 </TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="width: 1%; font-size: 10pt"> &nbsp; </TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right"> - </TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="width: 1%; font-size: 10pt"> &nbsp; </TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="width: 10%; font-size: 10pt; text-align: right"> * </TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> Handok, Inc. </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> (4) </TD><TD STYLE="font-size: 10pt"> &nbsp; </TD>
    <TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt; text-align: right"> 91,300,933 </TD><TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt"> &nbsp; </TD>
    <TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt; text-align: right"> 91,300,933 </TD><TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt"> &nbsp; </TD>
    <TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt; text-align: right"> - </TD><TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt"> &nbsp; </TD>
    <TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt; text-align: right"> * </TD><TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> Intervest 4th Industrial Revolution Fund II </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> (5) </TD><TD STYLE="font-size: 10pt"> &nbsp; </TD>
    <TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt; text-align: right"> 13,103,448 </TD><TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt"> &nbsp; </TD>
    <TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt; text-align: right"> 13,103,448 </TD><TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt"> &nbsp; </TD>
    <TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt; text-align: right"> - </TD><TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt"> &nbsp; </TD>
    <TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt; text-align: right"> * </TD><TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> The Welch Trust Agreement U/A DTD 4/3/96 </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> (6) </TD><TD STYLE="font-size: 10pt"> &nbsp; </TD>
    <TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt; text-align: right"> 9,049,702 </TD><TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt"> &nbsp; </TD>
    <TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt; text-align: right"> 6,635,409 </TD><TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt"> &nbsp; </TD>
    <TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt; text-align: right"> 2,414,293 </TD><TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt"> &nbsp; </TD>
    <TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt; text-align: right"> * </TD><TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> BVF Partners </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> (7) </TD><TD STYLE="font-size: 10pt"> &nbsp; </TD>
    <TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt; text-align: right"> 8,924,565 </TD><TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt"> &nbsp; </TD>
    <TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt; text-align: right"> 6,510,272 </TD><TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt"> &nbsp; </TD>
    <TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt; text-align: right"> 2,414,293 </TD><TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt"> &nbsp; </TD>
    <TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt; text-align: right"> * </TD><TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> Bigger Capital Fund, LP </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> (8) </TD><TD STYLE="font-size: 10pt"> &nbsp; </TD>
    <TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt; text-align: right"> 4,807,109 </TD><TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt"> &nbsp; </TD>
    <TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt; text-align: right"> 3,599,963 </TD><TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt"> &nbsp; </TD>
    <TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt; text-align: right"> 1,207,146 </TD><TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt"> &nbsp; </TD>
    <TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt; text-align: right"> * </TD><TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> 683 Capital Partners, LP </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> (9) </TD><TD STYLE="font-size: 10pt"> &nbsp; </TD>
    <TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt; text-align: right"> 4,462,282 </TD><TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt"> &nbsp; </TD>
    <TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt; text-align: right"> 3,255,136 </TD><TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt"> &nbsp; </TD>
    <TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt; text-align: right"> 1,207,146 </TD><TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt"> &nbsp; </TD>
    <TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt; text-align: right"> * </TD><TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> Starlight Investment Holdings Limited </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> (10) </TD><TD STYLE="font-size: 10pt"> &nbsp; </TD>
    <TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt; text-align: right"> 3,092,073 </TD><TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt"> &nbsp; </TD>
    <TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt; text-align: right"> 1,790,318 </TD><TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt"> &nbsp; </TD>
    <TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt; text-align: right"> 1,301,755 </TD><TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt"> &nbsp; </TD>
    <TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt; text-align: right"> * </TD><TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> Lincoln Park Capital Fund, LLC </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> (11) </TD><TD STYLE="font-size: 10pt"> &nbsp; </TD>
    <TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt; text-align: right"> 2,366,300 </TD><TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt"> &nbsp; </TD>
    <TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt; text-align: right"> 1,627,591 </TD><TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt"> &nbsp; </TD>
    <TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt; text-align: right"> 738,709 </TD><TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt"> &nbsp; </TD>
    <TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt; text-align: right"> * </TD><TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> Greg Clark </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> (12) </TD><TD STYLE="font-size: 10pt"> &nbsp; </TD>
    <TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt; text-align: right"> 1,784,905 </TD><TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt"> &nbsp; </TD>
    <TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt; text-align: right"> 1,302,046 </TD><TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt"> &nbsp; </TD>
    <TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt; text-align: right"> 482,859 </TD><TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt"> &nbsp; </TD>
    <TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt; text-align: right"> * </TD><TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> Cynergy Brookline Healthcare Fund LLC </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> (13) </TD><TD STYLE="font-size: 10pt"> &nbsp; </TD>
    <TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt; text-align: right"> 1,784,905 </TD><TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt"> &nbsp; </TD>
    <TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt; text-align: right"> 1,302,046 </TD><TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt"> &nbsp; </TD>
    <TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt; text-align: right"> 482,859 </TD><TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt"> &nbsp; </TD>
    <TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt; text-align: right"> * </TD><TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> Jeb Partners, L.P. </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> (14) </TD><TD STYLE="font-size: 10pt"> &nbsp; </TD>
    <TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt; text-align: right"> 1,784,905 </TD><TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt"> &nbsp; </TD>
    <TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt; text-align: right"> 1,302,046 </TD><TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt"> &nbsp; </TD>
    <TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt; text-align: right"> 482,859 </TD><TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt"> &nbsp; </TD>
    <TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt; text-align: right"> * </TD><TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> Richard A. Smith </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> (15) </TD><TD STYLE="font-size: 10pt"> &nbsp; </TD>
    <TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt; text-align: right"> 985,087 </TD><TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt"> &nbsp; </TD>
    <TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt; text-align: right"> 651,046 </TD><TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt"> &nbsp; </TD>
    <TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt; text-align: right"> 334,041 </TD><TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt"> &nbsp; </TD>
    <TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt; text-align: right"> * </TD><TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> Klaus Kretschmer </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> (16) </TD><TD STYLE="font-size: 10pt"> &nbsp; </TD>
    <TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt; text-align: right"> 1,288,025 </TD><TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt"> &nbsp; </TD>
    <TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt; text-align: right"> 651,046 </TD><TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt"> &nbsp; </TD>
    <TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt; text-align: right"> 636,979 </TD><TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt"> &nbsp; </TD>
    <TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt; text-align: right"> * </TD><TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> Gary Cook Family Trust </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> (17) </TD><TD STYLE="font-size: 10pt"> &nbsp; </TD>
    <TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt; text-align: right"> 892,475 </TD><TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt"> &nbsp; </TD>
    <TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt; text-align: right"> 651,046 </TD><TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt"> &nbsp; </TD>
    <TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt; text-align: right"> 241,429 </TD><TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt"> &nbsp; </TD>
    <TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt; text-align: right"> * </TD><TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> Dyke Rogers </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> (18) </TD><TD STYLE="font-size: 10pt"> &nbsp; </TD>
    <TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt; text-align: right"> 1,192,475 </TD><TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt"> &nbsp; </TD>
    <TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt; text-align: right"> 651,046 </TD><TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt"> &nbsp; </TD>
    <TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt; text-align: right"> 541,429 </TD><TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt"> &nbsp; </TD>
    <TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt; text-align: right"> * </TD><TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> Hessler Finance Ltd Via Guisan 6 </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> (19) </TD><TD STYLE="font-size: 10pt"> &nbsp; </TD>
    <TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt; text-align: right"> 960,658 </TD><TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt"> &nbsp; </TD>
    <TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt; text-align: right"> 651,046 </TD><TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt"> &nbsp; </TD>
    <TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt; text-align: right"> 309,612 </TD><TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt"> &nbsp; </TD>
    <TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt; text-align: right"> * </TD><TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> Steven S. Marco </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> (20) </TD><TD STYLE="font-size: 10pt"> &nbsp; </TD>
    <TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt; text-align: right"> 889,475 </TD><TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt"> &nbsp; </TD>
    <TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt; text-align: right"> 648,046 </TD><TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt"> &nbsp; </TD>
    <TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt; text-align: right"> 241,429 </TD><TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt"> &nbsp; </TD>
    <TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt; text-align: right"> * </TD><TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> District 2 Capital Fund LP </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> (21) </TD><TD STYLE="font-size: 10pt"> &nbsp; </TD>
    <TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt; text-align: right"> 517,241 </TD><TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt"> &nbsp; </TD>
    <TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt; text-align: right"> 517,241 </TD><TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt"> &nbsp; </TD>
    <TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt; text-align: right"> - </TD><TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt"> &nbsp; </TD>
    <TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt; text-align: right"> * </TD><TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> Neal Polan </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> (22) </TD><TD STYLE="font-size: 10pt"> &nbsp; </TD>
    <TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt; text-align: right"> 500,761 </TD><TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt"> &nbsp; </TD>
    <TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt; text-align: right"> 325,500 </TD><TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt"> &nbsp; </TD>
    <TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt; text-align: right"> 175,261 </TD><TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt"> &nbsp; </TD>
    <TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt; text-align: right"> * </TD><TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> Tatiana Kotchoubey </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> (23) </TD><TD STYLE="font-size: 10pt"> &nbsp; </TD>
    <TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt; text-align: right"> 446,215 </TD><TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt"> &nbsp; </TD>
    <TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt; text-align: right"> 325,500 </TD><TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt"> &nbsp; </TD>
    <TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt; text-align: right"> 120,715 </TD><TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt"> &nbsp; </TD>
    <TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt; text-align: right"> * </TD><TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> Vista Capital Investments, LLC </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> (24) </TD><TD STYLE="font-size: 10pt"> &nbsp; </TD>
    <TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt; text-align: right"> 446,215 </TD><TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt"> &nbsp; </TD>
    <TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt; text-align: right"> 325,500 </TD><TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt"> &nbsp; </TD>
    <TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt; text-align: right"> 120,715 </TD><TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt"> &nbsp; </TD>
    <TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt; text-align: right"> * </TD><TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> Water Street Capital, LLC </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> (25) </TD><TD STYLE="font-size: 10pt"> &nbsp; </TD>
    <TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt; text-align: right"> 446,215 </TD><TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt"> &nbsp; </TD>
    <TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt; text-align: right"> 325,500 </TD><TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt"> &nbsp; </TD>
    <TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt; text-align: right"> 120,715 </TD><TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt"> &nbsp; </TD>
    <TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt; text-align: right"> * </TD><TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> Jennifer Duncan Inheritor&rsquo;s Trust </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> (26) </TD><TD STYLE="font-size: 10pt"> &nbsp; </TD>
    <TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt; text-align: right"> 514,398 </TD><TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt"> &nbsp; </TD>
    <TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt; text-align: right"> 325,500 </TD><TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt"> &nbsp; </TD>
    <TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt; text-align: right"> 188,898 </TD><TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt"> &nbsp; </TD>
    <TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt; text-align: right"> * </TD><TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> Lagom LLC </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> (27) </TD><TD STYLE="font-size: 10pt"> &nbsp; </TD>
    <TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt; text-align: right"> 677,747 </TD><TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt"> &nbsp; </TD>
    <TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt; text-align: right"> 325,500 </TD><TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt"> &nbsp; </TD>
    <TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt; text-align: right"> 352,247 </TD><TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt"> &nbsp; </TD>
    <TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt; text-align: right"> * </TD><TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> Robert C. Jamo </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> (28) </TD><TD STYLE="font-size: 10pt"> &nbsp; </TD>
    <TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt; text-align: right"> 349,864 </TD><TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt"> &nbsp; </TD>
    <TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt; text-align: right"> 227,864 </TD><TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt"> &nbsp; </TD>
    <TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt; text-align: right"> 122,000 </TD><TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt"> &nbsp; </TD>
    <TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt; text-align: right"> * </TD><TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> Ethos Partners LLC </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> (29) </TD><TD STYLE="font-size: 10pt"> &nbsp; </TD>
    <TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt; text-align: right"> 267,748 </TD><TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt"> &nbsp; </TD>
    <TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt; text-align: right"> 195,319 </TD><TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt"> &nbsp; </TD>
    <TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt; text-align: right"> 72,429 </TD><TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt"> &nbsp; </TD>
    <TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt; text-align: right"> * </TD><TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> Bruce Conway </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> (30) </TD><TD STYLE="font-size: 10pt"> &nbsp; </TD>
    <TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt; text-align: right"> 223,130 </TD><TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt"> &nbsp; </TD>
    <TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt; text-align: right"> 162,773 </TD><TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt"> &nbsp; </TD>
    <TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt; text-align: right"> 60,357 </TD><TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt"> &nbsp; </TD>
    <TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt; text-align: right"> * </TD><TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> Charles Magolske </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> (31) </TD><TD STYLE="font-size: 10pt"> &nbsp; </TD>
    <TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt; text-align: right"> 223,130 </TD><TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt"> &nbsp; </TD>
    <TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt; text-align: right"> 162,773 </TD><TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt"> &nbsp; </TD>
    <TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt; text-align: right"> 60,357 </TD><TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt"> &nbsp; </TD>
    <TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt; text-align: right"> * </TD><TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> Peter A. Magolske </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> (32) </TD><TD STYLE="font-size: 10pt"> &nbsp; </TD>
    <TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt; text-align: right"> 223,130 </TD><TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt"> &nbsp; </TD>
    <TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt; text-align: right"> 162,773 </TD><TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt"> &nbsp; </TD>
    <TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt; text-align: right"> 60,357 </TD><TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt"> &nbsp; </TD>
    <TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt; text-align: right"> * </TD><TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> Harris Lydon </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> (33) </TD><TD STYLE="font-size: 10pt"> &nbsp; </TD>
    <TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt; text-align: right"> 614,268 </TD><TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt"> &nbsp; </TD>
    <TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt; text-align: right"> 162,773 </TD><TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt"> &nbsp; </TD>
    <TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt; text-align: right"> 451,495 </TD><TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt"> &nbsp; </TD>
    <TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt; text-align: right"> * </TD><TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> Timothy Hogue </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> (34) </TD><TD STYLE="font-size: 10pt"> &nbsp; </TD>
    <TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt; text-align: right"> 315,742 </TD><TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt"> &nbsp; </TD>
    <TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt; text-align: right"> 162,773 </TD><TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt"> &nbsp; </TD>
    <TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt; text-align: right"> 152,969 </TD><TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt"> &nbsp; </TD>
    <TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt; text-align: right"> * </TD><TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> Shoup Revocable Trust UAD 4/29/03 </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> (35) </TD><TD STYLE="font-size: 10pt"> &nbsp; </TD>
    <TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt; text-align: right"> 356,799 </TD><TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt"> &nbsp; </TD>
    <TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt; text-align: right"> 162,773 </TD><TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt"> &nbsp; </TD>
    <TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt; text-align: right"> 194,026 </TD><TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt"> &nbsp; </TD>
    <TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt; text-align: right"> * </TD><TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> Mark Coleman </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> (36) </TD><TD STYLE="font-size: 10pt"> &nbsp; </TD>
    <TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt; text-align: right"> 223,130 </TD><TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt"> &nbsp; </TD>
    <TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt; text-align: right"> 162,773 </TD><TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt"> &nbsp; </TD>
    <TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt; text-align: right"> 60,357 </TD><TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt"> &nbsp; </TD>
    <TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt; text-align: right"> * </TD><TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> Jimmie Harvey </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> (37) </TD><TD STYLE="font-size: 10pt"> &nbsp; </TD>
    <TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt; text-align: right"> 282,029 </TD><TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt"> &nbsp; </TD>
    <TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt; text-align: right"> 162,773 </TD><TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt"> &nbsp; </TD>
    <TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt; text-align: right"> 119,256 </TD><TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt"> &nbsp; </TD>
    <TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt; text-align: right"> * </TD><TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> AAR Associates LP </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> (38) </TD><TD STYLE="font-size: 10pt"> &nbsp; </TD>
    <TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt; text-align: right"> 178,514 </TD><TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt"> &nbsp; </TD>
    <TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt; text-align: right"> 130,228 </TD><TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt"> &nbsp; </TD>
    <TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt; text-align: right"> 48,286 </TD><TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt"> &nbsp; </TD>
    <TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt; text-align: right"> * </TD><TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> Ralph Finerman </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> (39) </TD><TD STYLE="font-size: 10pt"> &nbsp; </TD>
    <TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt; text-align: right"> 178,514 </TD><TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt"> &nbsp; </TD>
    <TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt; text-align: right"> 130,228 </TD><TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt"> &nbsp; </TD>
    <TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt; text-align: right"> 48,286 </TD><TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt"> &nbsp; </TD>
    <TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt; text-align: right"> * </TD><TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> Cynthia Finerman Living Trust </TD><TD STYLE="font: 10pt Times New Roman, Times, Serif"> &nbsp; </TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left"> (40) </TD><TD STYLE="font-size: 10pt"> &nbsp; </TD>
    <TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt; text-align: right"> 89,234 </TD><TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt"> &nbsp; </TD>
    <TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt; text-align: right"> 65,091 </TD><TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt"> &nbsp; </TD>
    <TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt; text-align: right"> 24,143 </TD><TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt"> &nbsp; </TD>
    <TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD><TD STYLE="font-size: 10pt; text-align: right"> * </TD><TD STYLE="font-size: 10pt; text-align: left"> &nbsp; </TD></TR>
</TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="margin: 0; font-size: 10pt"></P>

<!-- Field: Page; Sequence: 3; Value: 5 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0; font-size: 10pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in; text-align: left">*</TD><TD STYLE="text-align: justify">Represents ownership of less than 1%.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in; text-align: left">(1)</TD><TD STYLE="text-align: justify">Applicable percentage ownership is based on 293,320,891
shares of our common stock outstanding as of August 13, 2019.</TD>
</TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0; font-size: 10pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in; text-align: left">(2)</TD><TD STYLE="text-align: justify">Assumes the sale of all shares of common stock offered
in this prospectus.</TD>
</TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in; text-align: left">(3)</TD><TD STYLE="text-align: justify"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The
Selling Stockholder has voting and investment power over the shares. The address of the Selling Stockholder is 700 Daewangpangyo-ro
Korea Bio-Park, Building B, Bundang-gu, Seongnam-si, Gyeonggi-do 463-400, Republic of Korea. The Selling Stockholder is a greater
than 10% holder of the Company.</P>


</TD>
</TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in; text-align: left">(4)</TD><TD STYLE="text-align: justify"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The
Selling Stockholder has voting and investment power over the shares. The address of the Selling Stockholder is 132 Teheran-ro,
Gangnam-gu, Seoul 06235, Republic of Korea. The Selling Stockholder is a greater than 10% holder of the Company.</P>


</TD>
</TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">(5)</TD><TD>The Selling Stockholder has voting and investment power over the shares. The address of the Selling Stockholder is 511, Yeongdong-daero,
Gangnam-gu,, #1701, Trade Tower, Seoul, Korea, Republic of Korea.</TD></TR></TABLE>



<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in; text-align: left"> (6) </TD><TD STYLE="text-align: justify"> David Welch
                                         is the Trustee and has voting and investment power over the shares. The address of the
                                         Selling Stockholder is 217 Camino Al Lago, Atherton, CA 94027. David Welch is a former member of the Company&rsquo;s Board of Directors. </TD>
</TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in; text-align: left">(7)</TD><TD STYLE="text-align: justify">BVF Partners, LP as the General Partner has voting and
investment power over the shares. The address of the Selling Stockholder is One Sansome Street, 30th Floor, San Francisco, CA
94014.</TD>
</TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in; text-align: left"> (8) </TD><TD STYLE="text-align: justify"> Michael Bigger
                                         is the Managing Member and has voting and investment power over the shares. The address
                                         of the Selling Stockholder is 159 Jennings Road, Cold Spring Harbor, NY 11724. The Selling
                                         Stockholder is a related entity to District 2 Capital Fund LP. </TD>
</TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in; text-align: left">(9)</TD><TD STYLE="text-align: justify">The Selling Stockholder has voting and investment power
over the shares. The address of the Selling Stockholder is 3 Columbus Circle, Ste. 2205, New York, NY 10019.</TD>
</TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in; text-align: left">(10)</TD><TD STYLE="text-align: justify">The Selling Stockholder has voting and investment power
over the shares. The address of the Selling Stockholder is&nbsp;9 Burrard Street, St Helier, Jersey, JE4 5UE.</TD>
</TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in; text-align: left">(11)</TD><TD STYLE="text-align: justify">The Selling Stockholder has voting and investment power
over the shares. The address of the Selling Stockholder is 440 N. Wells Street, Suite 410, Chicago, IL 60654.</TD>
</TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in; text-align: left">(12)</TD><TD STYLE="text-align: justify">The Selling Stockholder has voting and investment power
over the shares. The address of the Selling Stockholder is 350 Ellis Street, Mountain View, California 94043.</TD>
</TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in; text-align: left">(13)</TD><TD STYLE="text-align: justify">The Selling Stockholder has voting and investment power
over the shares. The address of the Selling Stockholder is 257 Minorca Beach Way, Suite 1606, New Smyrna Beach, FL 32169.</TD>
</TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in; text-align: left">(14)</TD><TD STYLE="text-align: justify">The Selling Stockholder has voting and investment power
over the shares. The address of the Selling Stockholder is 3 West Hill Place, Boston, MA 02114.</TD>
</TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in; text-align: left">(15)</TD><TD STYLE="text-align: justify">The Selling Stockholder has voting and investment power
over the shares. The address of the Selling Stockholder is PO Box 124, 6B Nicol Rd, Shelter Island Heights, NY 11965.</TD>
</TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in; text-align: left">(16)</TD><TD STYLE="text-align: justify">The Selling Stockholder has voting and investment power
over the shares. The address of the Selling Stockholder is 46 Brook Way, Demarest, NJ 07627.</TD>
</TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in; text-align: left">(17)</TD><TD STYLE="text-align: justify">The Selling Stockholder has voting and investment power
over the shares. The address of the Selling Stockholder is 9103 Alta Drive Unit 704, Las Vegas, NV 89145.</TD>
</TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"></P>

<!-- Field: Page; Sequence: 4; Value: 5 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in; text-align: left">(18)</TD><TD STYLE="text-align: justify">The Selling Stockholder has voting and investment power
over the shares. The address of the Selling Stockholder is 1204 Olive Ave, Dalhart, Texas 79022.</TD>
</TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in; text-align: left">(19)</TD><TD STYLE="text-align: justify">The Selling Stockholder has voting and investment power
over the shares. The address of the Selling Stockholder is Via Guisan 6, PO Box 620, 6902 Lugano &ndash; Switzerland.</TD>
</TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in; text-align: left">(20)</TD><TD STYLE="text-align: justify">The Selling Stockholder has voting and investment power
over the shares. The address of the Selling Stockholder is 800 Fairfield Road NW, Atlanta, GA 30327.</TD>
</TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in; text-align: left"> (21) </TD><TD STYLE="text-align: justify"> Michael Bigger
                                         has voting and investment power over the shares. The address of the Selling Stockholder
                                         is 175 W Carver, Huntington, NY 11743. The Selling Stockholder is a related entity to
                                         Bigger Capital LP. </TD>
</TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in; text-align: left">(22)</TD><TD STYLE="text-align: justify">The Selling Stockholder has voting and investment power
over the shares. The address of the Selling Stockholder is 20 Cameron Drive, Greenwich, CT 06831.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; margin-left: 0in; text-indent: 0in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in; text-align: left">(23)</TD><TD STYLE="text-align: justify">The Selling Stockholder has voting and investment power
over the shares. The address of the Selling Stockholder is 467 Greenwich St, 4, New York, NY 10013.</TD>
</TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in; text-align: left">(24)</TD><TD STYLE="text-align: justify">The Selling Stockholder has voting and investment power
over the shares. The address of the Selling Stockholder is 120 Birmingham Drive, Suite 230, Cardiff by the Sea, CA 92007.</TD>
</TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in; text-align: left">(25)</TD><TD STYLE="text-align: justify">The Selling Stockholder has voting and investment power
over the shares. The address of the Selling Stockholder is 75 Wall Street, Suite 22-C, New York, NY 10005.</TD>
</TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in; text-align: left">(26)</TD><TD STYLE="text-align: justify">The Selling Stockholder has voting and investment power
over the shares. The address of the Selling Stockholder is 5514 Wenonah Dr, Dallas, TX 70209.</TD>
</TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in; text-align: left">(27)</TD><TD STYLE="text-align: justify">The Selling Stockholder has voting and investment power
over the shares. The address of the Selling Stockholder is 257 Mill Road, Germantown, NY 12526.</TD>
</TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in; text-align: left">(28)</TD><TD STYLE="text-align: justify">The Selling Stockholder has voting and investment power
over the shares. The address of the Selling Stockholder is 105 Hardscrabble Lake Drive, Chappaqua, NY 10514.</TD>
</TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in; text-align: left">(29)</TD><TD STYLE="text-align: justify">The Selling Stockholder has voting and investment power
over the shares. The address of the Selling Stockholder is 845 UN Plaza APT 61B, NY, NY 10017.</TD>
</TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in; text-align: left">(30)</TD><TD STYLE="text-align: justify">The Selling Stockholder has voting and investment power
over the shares. The address of the Selling Stockholder is 5403 Drane Dr., Dallas, TX 75209.</TD>
</TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in; text-align: left">(31)</TD><TD STYLE="text-align: justify">The Selling Stockholder has voting and investment power
over the shares. The address of the Selling Stockholder is 1012 S. Garfield St., Denver, CO 80209.</TD>
</TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in; text-align: left">(32)</TD><TD STYLE="text-align: justify">The Selling Stockholder has voting and investment power
over the shares. The address of the Selling Stockholder is 6500 24th Ave NW, Seattle, WA 98117.</TD>
</TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in; text-align: left">(33)</TD><TD STYLE="text-align: justify">The Selling Stockholder has voting and investment power
over the shares. The address of the Selling Stockholder is 17 White Street, 2B, New York, NY 10013.</TD>
</TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in; text-align: left">(34)</TD><TD STYLE="text-align: justify">The Selling Stockholder has voting and investment power
over the shares. The address of the Selling Stockholder is PO Box 540, Shelter Island Heights, NY 11965.</TD>
</TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in; text-align: left">(35)</TD><TD STYLE="text-align: justify">The Selling Stockholder has voting and investment power
over the shares. The address of the Selling Stockholder is E. 4370 Anklam Lane, Marion, WI 54950.</TD>
</TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"></P>

<!-- Field: Page; Sequence: 5; Value: 5 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in; text-align: left">(36)</TD><TD STYLE="text-align: justify">The Selling Stockholder has voting and investment power
over the shares. The address of the Selling Stockholder is 10 Chris Eliot Court, Cockeysville, MD 21030.</TD>
</TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in; text-align: left">(37)</TD><TD STYLE="text-align: justify">The Selling Stockholder has voting and investment power
over the shares. The address of the Selling Stockholder is 3741 East Fairway, Birmingham, AL 35213.</TD>
</TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in; text-align: left">(38)</TD><TD STYLE="text-align: justify">The Selling Stockholder has voting and investment power
over the shares. The address of the Selling Stockholder is 1250 Fourth Street, 5th Floor, Santa Monica, CA 90401.</TD>
</TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in; text-align: left">(39)</TD><TD STYLE="text-align: justify">The Selling Stockholder has voting and investment power
over the shares. The address of the Selling Stockholder is 16590 Via Floresta, Pacific Palisades, CA 90272.</TD>
</TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in; text-align: left">(40)</TD><TD STYLE="text-align: justify">The Selling Stockholder has voting and investment power
over the shares. The address of the Selling Stockholder is 16590 Via Floresta, Pacific Palisades, CA 90272.</TD>
</TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><A NAME="PLANOFDISTRIBUTION"></A>PLAN OF DISTRIBUTION</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">The Selling Stockholders,
which as used herein includes donees, pledgees, transferees or other successors-in-interest selling shares of common stock or interests
in shares of common stock received after the date of this prospectus from a selling stockholder as a gift, pledge, partnership
distribution or other transfer, may, from time to time, sell, transfer or otherwise dispose of any or all of their shares of common
stock or interests in shares of common stock on any stock exchange, market or trading facility on which the shares are traded or
in private transactions. These dispositions may be at fixed prices, at prevailing market prices at the time of sale, at prices
related to the prevailing market price, at varying prices determined at the time of sale, or at negotiated prices.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">The Selling Stockholders
may use any one or more of the following methods when disposing of shares or interests therein:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">ordinary brokerage transactions and transactions in which
the broker-dealer solicits purchasers;</TD>
</TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">block trades in which the broker-dealer will attempt
to sell the shares as agent, but may position and resell a portion of the block as principal to facilitate the transaction;</TD>
</TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">purchases by a broker-dealer as principal and resale
by the broker-dealer for its account;</TD>
</TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">an exchange distribution in accordance with the rules
of the applicable exchange;</TD>
</TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">privately negotiated transactions;</TD>
</TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">short sales effected after the date the registration
statement of which this prospectus is a part is declared effective by the SEC;</TD>
</TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">through the writing or settlement of options or other
hedging transactions, whether through an options exchange or otherwise;</TD>
</TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">broker-dealers may agree with the Selling Stockholders
to sell a specified number of such shares at a stipulated price per share;</TD>
</TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">a combination of any such methods of sale; and</TD>
</TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">any other method permitted by applicable law.</TD>
</TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"></P>

<!-- Field: Page; Sequence: 6; Value: 5 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">The Selling Stockholders
may, from time to time, pledge or grant a security interest in some or all of the shares of common stock owned by them and, if
they default in the performance of their secured obligations, the pledgees or secured parties may offer and sell the shares of
common stock, from time to time, under this prospectus, or under an amendment to this prospectus under Rule 424(b)(3) or other
applicable provision of the Securities Act amending the list of Selling Stockholders to include the pledgee, transferee or other
successors in interest as Selling Stockholders under this prospectus. The Selling Stockholders also may transfer the shares of
common stock in other circumstances, in which case the transferees, pledgees or other successors in interest will be the selling
beneficial owners for purposes of this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">In connection with the
sale of our common stock or interests therein, the Selling Stockholders may enter into hedging transactions with broker-dealers
or other financial institutions, which may in turn engage in short sales of the common stock in the course of hedging the positions
they assume. The Selling Stockholders may also sell shares of our common stock short and deliver these securities to close out
their short positions, or loan or pledge the common stock to broker-dealers that in turn may sell these securities. The Selling
Stockholders may also enter into option or other transactions with broker-dealers or other financial institutions or the creation
of one or more derivative securities which require the delivery to such broker-dealer or other financial institution of shares
offered by this prospectus, which shares such broker-dealer or other financial institution may resell pursuant to this prospectus
(as supplemented or amended to reflect such transaction).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">The aggregate proceeds
to the Selling Stockholders from the sale of the common stock offered by them will be the purchase price of the common stock less
discounts or commissions, if any. Each of the Selling Stockholders reserves the right to accept and, together with their agents
from time to time, to reject, in whole or in part, any proposed purchase of common stock to be made directly or through agents.
We will not receive any of the proceeds from this offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">The Selling Stockholders
also may resell all or a portion of the shares in open market transactions in reliance upon Rule 144 under the Securities Act,
provided that they meet the criteria and conform to the requirements of that rule.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">The Selling Stockholders
and any underwriters, broker-dealers or agents that participate in the sale of the common stock or interests therein may be &ldquo;underwriters&rdquo;
within the meaning of Section 2(11) of the Securities Act. Any discounts, commissions, concessions or profit they earn on any resale
of the shares may be underwriting discounts and commissions under the Securities Act. Selling stockholders who are &ldquo;underwriters&rdquo;
within the meaning of Section 2(11) of the Securities Act will be subject to the prospectus delivery requirements of the Securities
Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">To the extent required,
the shares of our common stock to be sold, the names of the Selling Stockholders, the respective purchase prices and public offering
prices, the names of any agents, dealer or underwriter, any applicable commissions or discounts with respect to a particular offer
will be set forth in an accompanying prospectus supplement or, if appropriate, a post-effective amendment to the registration statement
that includes this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">In order to comply with
the securities laws of some states, if applicable, the common stock may be sold in these jurisdictions only through registered
or licensed brokers or dealers. In addition, in some states the common stock may not be sold unless it has been registered or qualified
for sale or an exemption from registration or qualification requirements is available and is complied with.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">We have advised the Selling
Stockholders that the anti-manipulation rules of Regulation M under the Exchange Act may apply to sales of shares in the market
and to the activities of the Selling Stockholders and their affiliates. In addition, to the extent applicable we will make copies
of this prospectus (as it may be supplemented or amended from time to time) available to the Selling Stockholders for the purpose
of satisfying the prospectus delivery requirements of the Securities Act. The Selling Stockholders may indemnify any broker-dealer
that participates in transactions involving the sale of the shares against certain liabilities, including liabilities arising under
the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">Our common stock is quoted
on OTCQB under the symbol &ldquo;RZLT&rdquo;.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 7; Value: 5 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><A NAME="LEGALMATTERS"></A>LEGAL MATTERS</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The validity of the shares of our common
stock offered hereby and certain other legal matters will be passed upon for us by the law firm of Dorsey &amp; Whitney LLP.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><A NAME="EXPERTS"></A>EXPERTS</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Effective October 1, 2018, EKS&amp;H LLLP,
our independent registered public accounting firm, combined with Plante Moran PLLC. As a result of this transaction, on October
16, 2018, we engaged Plante Moran PLLC as our new independent registered public accounting firm. EKS&amp;H LLLP has audited our
consolidated financial statements included in our Annual Report on Form 10-K, for the years ended June 30, 2018 and 2017, which
are incorporated by reference in this prospectus and elsewhere in the registration statement. Our financial statements are incorporated
by reference in reliance on EKS&amp;H LLLP&rsquo;s report, given their authority as experts in accounting and auditing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><A NAME="WHEREYOUCANFINDADDITIONALINFORMATION"></A>WHERE YOU CAN FIND
ADDITIONAL INFORMATION</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We file annual reports, quarterly reports,
current reports, and proxy and information statements and other information with the SEC. You may read and copy materials that
we have filed with the SEC at the SEC public reference room at 100 F Street, N.E., Washington, D.C. 20549. Please call the SEC
at 1-800-SEC-0330 for further information on the public reference room. Copies of reports and other information from us are available
on the SEC&rsquo;s website at http://www.sec.gov. Such filings are also available at our website at http://www.rezolutebio.com.
Website materials are not a part of this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><A NAME="DOCUMENTSINCORPORATEDBYREFERENCE"></A>DOCUMENTS INCORPORATED
BY REFERENCE</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The SEC allows us to &ldquo;incorporate
by reference&rdquo; the information that we have filed with it, meaning we can disclose important information to you by referring
you to those documents already on file with the SEC. The information incorporated by reference is considered to be part of this
prospectus except for any information that is superseded by other information that is included in this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This filing incorporated by reference the
following documents, which we have previously filed with the SEC pursuant to the Exchange Act:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">Annual Report on Form 10-K for the year ended June 30, 2018 as filed with the SEC on <A HREF="http://www.sec.gov/Archives/edgar/data/1509261/000114420418053849/tv503852_10k.htm">October 15, 2018</A> and as amended on <A HREF="http://www.sec.gov/Archives/edgar/data/1509261/000114420418066747/tv509531_10ka.htm">December 31, 2018</A>;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">Quarterly Report on Form 10-Q for the quarter ended September 30, 2018 as filed with the SEC on
<A HREF="http://www.sec.gov/Archives/edgar/data/1509261/000114420418064695/tv506226_10q.htm">December 14, 2018</A>;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">Quarterly Report on Form 10-Q for the quarter ended December 31, 2018 as filed with the SEC on
<A HREF="http://www.sec.gov/Archives/edgar/data/1509261/000114420419007974/tv512474_10q.htm">February 14, 2019</A>;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">Quarterly Report on Form 10-Q for the quarter ended March 31, 2019 as filed with the SEC on <A HREF="http://www.sec.gov/Archives/edgar/data/1509261/000114420419025189/tv519864_10q.htm">May 10, 2019</A>;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">Current Reports on Form 8-K filed with the SEC on <A HREF="http://www.sec.gov/Archives/edgar/data/1509261/000091228219000005/rezolute8kno2_011119.htm">January 11, 2019</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1509261/000114420419004081/tv512083_8-k.htm">January 31, 2019</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1509261/000114420419022478/tv520059_8k.htm">April 30, 2019</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1509261/000091228219000086/rezolute8k_072919.htm">July 30, 2019</A> and <A HREF="http://www.sec.gov/Archives/edgar/data/1509261/000091228219000093/rezolute8k_081219.htm">August 13, 2019</A>; and</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol; font-size: 10pt">&middot;</FONT></TD><TD STYLE="text-align: justify">Our Definitive Proxy Statement on Schedule 14A for our 2018 annual meeting of stockholders filed
with the SEC on <A HREF="http://www.sec.gov/Archives/edgar/data/1509261/000114420419018452/tv518301_def14a.htm">April 5, 2019</A>.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In addition, all documents subsequently
filed by us with the SEC pursuant to Sections 13(a), 13(c), 14 or 15(d) of the Exchange Act, prior to the termination of the offering,
shall be deemed to be incorporated by reference into this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 8; Value: 5 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">We will provide, without charge, to each
person, including any beneficial owner, to whom this prospectus is delivered, on the written or oral request of such person, a
copy of any or all of the reports or documents incorporated by reference in this prospectus, but not delivered with this prospectus.
Any request may be made by writing or telephoning us at the following address or telephone number:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Rezolute, Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">201 Redwood Shores Pkwy, Suite 315,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Redwood City, CA 94065</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Attn: Investor Relations</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">650-206-4507</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">investor-relations@rezolutebio.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">You may also access the documents incorporated
by reference into this prospectus at our website address at www.rezolutebio.com. The other information and content contained on
or linked from our website are not part of this prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<!-- Field: Page; Sequence: 9; Value: 5 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><A NAME="PARTII"></A>PART II &ndash; INFORMATION
NOT REQUIRED IN PROSPECTUS</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Other Expenses of Issuance and Distribution</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The fees and expenses to be paid in connection
with the distribution of securities being registered hereby are estimated as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 40%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 77%; font: 10pt Times New Roman, Times, Serif; text-align: justify">SEC registration fee</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="width: 20%; font: 10pt Times New Roman, Times, Serif; text-align: right">5,891</TD><TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">Accounting fees and expenses</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">5,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; padding-bottom: 1pt">Legal fees and expenses</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">10,000</TD><TD STYLE="padding-bottom: 1pt; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font: bold 10pt Times New Roman, Times, Serif; text-align: justify">Total</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">$</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">20,891</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
</TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Indemnification of Directors and Officers</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Section 145 of the Delaware General Corporation
Law provides that a corporation has the power to indemnify a director, officer, employee or agent of the corporation and certain
other persons serving at the request of the corporation in related capacities against amounts paid and expenses incurred in connection
with an action or proceeding to which he is or is threatened to be made a party by reason of such position, if such person shall
have acted in good faith and in a manner he reasonably believed to be in or not opposed to the best interests of the corporation,
and, in any criminal proceeding, if such person had no reasonable cause to believe his conduct was unlawful; provided that, in
the case of actions brought by or in the right of the corporation, no indemnification shall be made with respect to any matter
as to which such person shall have been adjudged to be liable to the corporation unless and only to the extent that the adjudicating
court determines that such indemnification is proper under the circumstances.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our Certificate of Incorporation and Bylaws
provide that our directors and officers will be indemnified by us to the fullest extent authorized by Delaware General Corporation
Law. In addition, the Certificate of Incorporation provides, as permitted by Section 102(b)(7) of the Delaware General Corporation
Law, that our directors will not be liable for monetary damages to us for breaches of their fiduciary duty as directors, unless
they (i) violated their duty of loyalty to us or our stockholders, (ii) acted, or failed to act, in good faith, (iii) acted with
intentional misconduct, (iv) knowingly or intentionally violated the law, (v) authorized unlawful payments of dividends, unlawful
stock purchases or unlawful redemptions, or (vi) derived an improper personal benefit from their actions as directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Our Bylaws also permit us to secure insurance
on behalf of any officer, director or employee for any liability arising out of his or her actions, regardless of whether Delaware
General Corporation Law would permit indemnification. We have purchased a policy of directors&rsquo; and officers&rsquo; liability
insurance that insures our directors and officers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The limitations of liability and indemnification
provisions in our Certificate of Incorporation and Bylaws may discourage stockholders from bringing a lawsuit against directors
for breach of their fiduciary duty. These provisions may also have the effect of reducing the likelihood of derivative litigation
against directors and officers, even though such an action, if successful, might otherwise benefit our stockholders and us. In
addition, your investment may be adversely affected to the extent we pay the costs of settlement and damage awards against directors
and officers pursuant to these indemnification provisions. We believe that these provisions, the insurance and the indemnity agreements
are necessary to attract and retain talented and experienced directors and officers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Insofar as indemnification for liabilities
arising under the Securities Act of 1933 may be permitted to directors, officers or persons controlling the registrant pursuant
to the foregoing provisions, the registrant has been advised that, in the opinion of the Securities and Exchange Commission such
indemnification is against public policy as expressed in Act and is, therefore, unenforceable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Recent Sales of Unregistered Securities</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">In the past three years we have offered
and sold the following securities in unregistered transactions pursuant to exemptions under the United States Securities Act of
1933, as amended (the &ldquo;<B>Securities Act</B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 10; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">1.</TD><TD STYLE="text-align: justify">On March 2, 2016, we issued 1,716,487 shares of Series A Preferred Stock in a Series A Financing
to six investors for an aggregate consideration of $3,347,500. We paid the placement agents cash compensation of $230,174 and we
also issued warrants exercisable into 414,546 shares of our common stock. The issuance was made in reliance upon an exemption from
registration under Section 4(a)(2) of the Securities Act.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">2.</TD><TD STYLE="text-align: justify">On April 12, 2016, we issued 512,820 shares of Series A Preferred Stock in a Series A Financing
to one investor for an aggregate consideration of $1,000,000. The issuance was made in reliance upon an exemption from registration
under Section 4(a)(2) of the Securities Act.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">3.</TD><TD STYLE="text-align: justify">On April 29, 2016, we issued 161,679 shares of our common stock in the Unit Financing to three
investors for an aggregate consideration of $177,847. The issuance was made in reliance upon an exemption from registration under
Section 4(a)(2) of the Securities Act.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">4.</TD><TD STYLE="text-align: justify">On May 31, 2016, we issued 3,001,888 shares of our common stock in the Unit Financing to 26 investors
for an aggregate consideration of $3,302,077. The issuance was made in reliance upon an exemption from registration under Section
4(a)(2) of the Securities Act.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">5.</TD><TD STYLE="text-align: justify">On June 24, 2016, we issued 715,909 shares to of our common stock in the Unit Financing to 15 investors
for an aggregate consideration of $787,500. We paid the placement agent cash compensation of $61,798 and we also issued warrants
exercisable into 71,591 shares of common stock. The issuance was made in reliance upon an exemption from registration under Section
4(a)(2) of the Securities Act.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">6.</TD><TD STYLE="text-align: justify">On June 28, 2016, we issued 995,543 shares of our common stock in the Unit Financing to 14 investors
for an aggregate consideration of $1,095,097. The issuance was made in reliance upon an exemption from registration under Section
4(a)(2) of the Securities Act.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">7.</TD><TD STYLE="text-align: justify">On July 29, 2016, we issued 418,182 shares of our common stock in the Unit Financing to nine investors
for an aggregate consideration of $460,000. The issuance was made in reliance upon an exemption from registration under Section
4(a)(2) of the Securities Act.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">8.</TD><TD STYLE="text-align: justify">On September 30, 2016, we issued 2,029,454 shares of our common stock in the Unit Financing to
25 investors for an aggregate consideration of $2,232,399. The issuance was made in reliance upon an exemption from registration
under Section 4(a)(2) of the Securities Act.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">9.</TD><TD STYLE="text-align: justify">On October 6, 2016, we issued 2,376,455 shares of our common stock in the Unit Financing to 24
investors for an aggregate consideration of $2,614,101. We paid the placement agent cash compensation of $339,833 and we also issued
warrants exercisable into 978,152 shares of common stock. The issuance was made in reliance upon an exemption from registration
under Section 4(a)(2) of the Securities Act.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">10.</TD><TD STYLE="text-align: justify">On October 7, 2016, we issued 909,091 shares of our common stock in the Unit financing to one investor
for an aggregate consideration of $1,000,000. The issuance was made in reliance upon an exemption from registration under Section
4(a)(2) of the Securities Act.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">11.</TD><TD STYLE="text-align: justify">On October 13, 2016, we issued 50,000 shares of our common stock in the Unit financing to one investor
for an aggregate consideration of $55,000. The issuance was made in reliance upon an exemption from registration under Section
4(a)(2) of the Securities Act.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">12.</TD><TD STYLE="text-align: justify">On March 6, 2017, we issued 4,500,000 shares of our common stock in the stock financing to three
investors for an aggregate consideration of $4,500,000. The issuance was made in reliance upon an exemption from registration under
Section 4(a)(2) of the Securities Act.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">13.</TD><TD STYLE="text-align: justify">On April 18, 2017, we issued 2,226,190 shares of our common stock in the stock financing to two
investors for an aggregate consideration of $2,226,190. The issuance was made in reliance upon an exemption from registration under
Section 4(a)(2) of the Securities Act.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"></P>

<!-- Field: Page; Sequence: 11; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">14.</TD><TD STYLE="text-align: justify">On June 30, 2017, we issued 1,550,000 shares of our common stock in the stock financing to five
investors for an aggregate consideration of $1,550,000. The issuance was made in reliance upon an exemption from registration under
Section 4(a)(2) of the Securities Act.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">15.</TD><TD STYLE="text-align: justify">On July 18, 2017, we issued 4,500,000 shares of our common stock in the stock financing to two
investors for an aggregate consideration of $4,500,000. The issuance was made in reliance upon an exemption from registration under
Section 4(a)(2) of the Securities Act.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">16.</TD><TD STYLE="text-align: justify">On April 2, 2018, we issued convertible promissory notes for an aggregate consideration of $5,300,000.
The issuance was made in reliance upon an exemption from registration under Section 4(a)(2) of the Securities Act.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">17.</TD><TD STYLE="text-align: justify">On January 30, 2019, we issued 2,500,000 shares of our Series AA Preferred Stock for an aggregate
consideration of $25,000,000. The issuance was made in reliance upon an exemption from registration under Section 4(a)(2) of the
Securities Act.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">18.</TD><TD STYLE="text-align: justify">On January 30, 2019, we issued 767,515 shares of our Series AA Preferred Stock upon the automatic
conversion of certain outstanding convertible promissory notes. The issuance was made in reliance upon an exemption from registration
under Section 4(a)(2) of the Securities Act.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">19.</TD><TD STYLE="text-align: justify">On April 30, 2019, we issued 148,523,540 shares of our common stock upon the conversion of the
Series AA Preferred Stock. The issuance was made in reliance upon an exemption from registration under Section 4(a)(2) of the Securities
Act.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">20.</TD><TD STYLE="text-align: justify">On July 31, 2019, we issued 69,827,584 shares of our common stock. The issuance was made in reliance
upon an exemption from registration under Section 4(a)(2) of the Securities Act.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">21.</TD><TD STYLE="text-align: justify">On August 7, 2019, we issued 13,103,448 shares of our
common stock. The issuance was made in reliance upon an exemption from registration under Section 4(a)(2) of the Securities Act.</TD>
</TR></TABLE>



<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Exhibits</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">A list of exhibits filed herewith or incorporated
by reference is contained in the Exhibit Index which is incorporated herein by reference.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">Undertakings</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">(a)</TD><TD STYLE="text-align: justify">The undersigned registrant hereby undertakes:</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(1)</TD><TD STYLE="text-align: justify">To file, during any period in which offers or sales are being made, a post-effective amendment
to this registration statement:</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">(i)</TD><TD STYLE="text-align: justify">To include any prospectus required by Section&nbsp;10(a)(3)&nbsp;of the Securities Act of 1933;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">(ii)</TD><TD STYLE="text-align: justify">To reflect in the prospectus any facts or events arising after the effective date of the registration
statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental
change in the information set forth in the registration statement.&nbsp; Notwithstanding the foregoing, any increase or decrease
in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and
any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed
with the Commission pursuant to Rule&nbsp;424(b)&nbsp;if, in the aggregate, the changes in volume and price represent no more than
20 percent change in the maximum aggregate offering price set forth in the &ldquo;Calculation of Registration Fee&rdquo; table
in the effective registration statement;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">(iii)</TD><TD STYLE="text-align: justify">To include any material information with respect to the plan of distribution not previously disclosed
in the registration statement or any material change to such information in the Registration Statement;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in">(a)</TD><TD STYLE="text-align: justify"><I>provided, however</I>, that:</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"></P>

<!-- Field: Page; Sequence: 12; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in"></TD><TD STYLE="width: 0.25in">(b)</TD><TD STYLE="text-align: justify">paragraphs (a)(1)(i), (ii)&nbsp;and (iii)&nbsp;above do not apply if the registration statement
is on Form&nbsp;S-1 (&sect;&nbsp;239.11 of this chapter), Form&nbsp;S-3 (&sect;&nbsp;239.13 of this chapter), Form&nbsp;SF-3 (&sect;&nbsp;239.45
of this chapter) or Form&nbsp;F-3 (&sect;&nbsp;239.33 of this chapter) and the information required to be included in a post-effective
amendment by those paragraphs is contained in reports filed with or furnished to the Commission by the registrant pursuant to section&nbsp;13
or section&nbsp;15(d)&nbsp;of the Securities Exchange Act of 1934 (15 U.S.C. 78m or 78<I>o</I>(d)) that are incorporated by reference
in the registration statement, or, as to a registration statement on Form&nbsp;S-3, Form&nbsp;SF-3 or Form&nbsp;F-3, is contained
in a form of prospectus filed pursuant to &sect;&nbsp;230.424(b)&nbsp;of this chapter that is part of the registration statement.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(2)</TD><TD STYLE="text-align: justify">That, for the purpose of determining any liability under the Securities Act of 1933, each such
post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the
offering of such securities at that time shall be deemed to be the initial <I>bona fide </I>offering thereof; and</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(3)</TD><TD STYLE="text-align: justify">To remove from registration by means of a post-effective amendment any of the securities being
registered which remain unsold at the termination of the offering;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(1)</TD><TD STYLE="text-align: justify">That, for the purpose of determining liability under the Securities Act of 1933 to any purchaser,
each prospectus filed pursuant to Rule&nbsp;424(b)&nbsp;as part of a registration statement relating to an offering, other than
registration statements relying on Rule&nbsp;430B or other than prospectuses filed in reliance on Rule&nbsp;430A, shall be deemed
to be part of and included in the registration statement as of the date it is first used after effectiveness.&nbsp; <I>Provided,
however, </I>that no statement made in a registration statement or prospectus that is part of the registration statement or made
in a document incorporated or deemed incorporated by reference into the registration statement or prospectus that is part of the
registration statement will, as to a purchaser with a time of contract of sale prior to such first use, supersede or modify any
statement that was made in the registration statement or prospectus that was part of the registration statement or made in any
such document immediately prior to such date of first use; and</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">(b)</TD><TD STYLE="text-align: justify">The undersigned registrant hereby undertakes that insofar as indemnification for liabilities arising
under the Securities Act may be permitted to directors, officers and controlling persons of the registrant pursuant to the foregoing
provisions, or otherwise, the registrant has been advised that in the opinion of the Commission, such indemnification is against
public policy as expressed in the Securities Act and is, therefore, unenforceable.&nbsp; In the event that a claim for indemnification
against such liabilities (other than the payment by the registrant of expenses incurred or paid by a director, officer or controlling
person of the registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or
controlling person in connection with the securities being registered, the registrant will, unless in the opinion of its counsel
the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification
by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif"></P>

<!-- Field: Page; Sequence: 13; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">II-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><A NAME="signature"></A>SIGNATURES</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> Pursuant to the requirements of the
Securities Act of 1933, the registrant has duly caused this registration statement to be signed on its behalf by the undersigned,
thereunto duly authorized in the City of Redwood City, State of California, on August 16, 2019. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR>
<TD STYLE="vertical-align: top; width: 50%">&nbsp;</TD>
<TD STYLE="vertical-align: bottom; width: 5%">&nbsp;</TD>
<TD STYLE="vertical-align: bottom; width: 45%"><B>REZOLUTE, INC.</B></TD></TR>
<TR>
<TD>&nbsp;</TD>
<TD COLSPAN="2">&nbsp;</TD></TR>
<TR>
<TD STYLE="vertical-align: top">&nbsp;</TD>
<TD STYLE="vertical-align: bottom">By:</TD>
<TD STYLE="vertical-align: bottom; border-bottom: black 1pt solid">/s/ Nevan Elam</TD></TR>
<TR>
<TD STYLE="vertical-align: top">&nbsp;</TD>
<TD STYLE="vertical-align: bottom">&nbsp;</TD>
<TD STYLE="vertical-align: bottom">Nevan Elam</TD></TR>
<TR>
<TD STYLE="vertical-align: top">&nbsp;</TD>
<TD STYLE="vertical-align: bottom">&nbsp;</TD>
<TD STYLE="vertical-align: bottom"><I>Chief Executive Officer</I></TD></TR>
<TR>
<TD STYLE="vertical-align: top">&nbsp;</TD>
<TD STYLE="vertical-align: bottom">&nbsp;</TD>
<TD STYLE="vertical-align: bottom">(Principal Executive Officer)</TD></TR>
<TR>
<TD STYLE="vertical-align: top">&nbsp;</TD>
<TD STYLE="vertical-align: bottom">&nbsp;</TD>
<TD STYLE="vertical-align: bottom">&nbsp;</TD></TR>
<TR>
<TD STYLE="vertical-align: top">&nbsp;</TD>
<TD STYLE="vertical-align: bottom">By:</TD>
<TD STYLE="vertical-align: bottom; border-bottom: black 1pt solid">/s/ Keith Vendola</TD></TR>
<TR>
<TD STYLE="vertical-align: top">&nbsp;</TD>
<TD STYLE="vertical-align: bottom">&nbsp;</TD>
<TD STYLE="vertical-align: bottom">Keith Vendola</TD></TR>
<TR>
<TD STYLE="vertical-align: top">&nbsp;</TD>
<TD STYLE="vertical-align: bottom">&nbsp;</TD>
<TD STYLE="vertical-align: bottom"><I>Chief Financial Officer</I></TD></TR>
<TR>
<TD STYLE="vertical-align: top">&nbsp;</TD>
<TD STYLE="vertical-align: bottom">&nbsp;</TD>
<TD STYLE="vertical-align: bottom">(Principal Financial Officer)</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> Pursuant to the requirements of the
Securities Act of 1933, as amended, this registration statement has been signed by the following persons in the capacities and
on the dates indicated. </P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 30%; border-bottom: black 1pt solid; text-align: center"> <B>Signature</B> </TD>
    <TD STYLE="width: 2%; text-align: center"> &nbsp; </TD>
    <TD STYLE="width: 45%; border-bottom: black 1pt solid; text-align: center"> <B>Title</B> </TD>
    <TD STYLE="width: 2%; text-align: center"> &nbsp; </TD>
    <TD STYLE="width: 21%; border-bottom: black 1pt solid; text-align: center"> <B>Date</B> </TD></TR>
<TR STYLE="vertical-align: top">
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: black 1pt solid"> /s/ Nevan Elam </TD>
    <TD> &nbsp; </TD>
    <TD> Chief Executive Officer and Director </TD>
    <TD> &nbsp; </TD>
    <TD> August 16, 2019 </TD></TR>
<TR STYLE="vertical-align: top">
    <TD> Nevan Elam </TD>
    <TD> &nbsp; </TD>
    <TD> (Principal Executive Officer) </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
<TR STYLE="vertical-align: top">
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: black 1pt solid"> * </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> August 16, 2019 </TD></TR>
<TR STYLE="vertical-align: top">
    <TD> Young-Jin Kim </TD>
    <TD> &nbsp; </TD>
    <TD> Director </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
<TR STYLE="vertical-align: top">
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: black 1pt solid"> * </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> August 16, 2019 </TD></TR>
<TR STYLE="vertical-align: top">
    <TD> Young Chul Sung, PH.D. </TD>
    <TD> &nbsp; </TD>
    <TD> Director </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
<TR STYLE="vertical-align: top">
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: black 1pt solid"> * </TD>
    <TD> &nbsp; </TD>
    <TD> Chief Financial Officer </TD>
    <TD> &nbsp; </TD>
    <TD> August 16, 2019 </TD></TR>
<TR STYLE="vertical-align: top">
    <TD> Keith Vendola </TD>
    <TD> &nbsp; </TD>
    <TD> (Principal Financial Officer) </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
<TR STYLE="vertical-align: top">
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
<TR STYLE="vertical-align: top">
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid"> * /s/ Nevan Elam </TD>
    <TD> &nbsp; </TD>
    <TD> Attorney-in-fact </TD>
    <TD> &nbsp; </TD>
    <TD> August 16, 2019 </TD></TR>
<TR STYLE="vertical-align: top">
    <TD> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Nevan Elam </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
<TR STYLE="vertical-align: top">
    <TD> &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD>
    <TD> &nbsp; </TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 14; Options: NewSection; Value: 18 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in"><A NAME="Exhibiindex"></A>EXHIBIT INDEX</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 10%; text-align: justify"><B>Exhibit No.</B></TD>
    <TD STYLE="width: 90%; text-align: center"><B>Description</B></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1509261/000091228213000073/ex2_1.htm"><B>2.1</B></A></TD>
    <TD STYLE="text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1509261/000091228213000073/ex2_1.htm">Share Exchange and Reorganization Agreement, January 31, 2013 (incorporated by reference to the Company&rsquo;s Form 8-K filing on February 6, 2013)</A></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1509261/000091228213000025/ex2_1.htm"><B>2.2</B></A></TD>
    <TD STYLE="text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1509261/000091228213000025/ex2_1.htm">Plan of Conversion, dated January 10, 2013 (incorporated by reference to Exhibit 2.1 of the Company&rsquo;s Form 8-K filing on January 11, 2013)</A></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1509261/000091228213000025/ex3_1.htm"><B>3.1</B></A></TD>
    <TD STYLE="text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1509261/000091228213000025/ex3_1.htm">Articles of Conversion, dated January 10, 2013 (incorporated by reference to Exhibit 3.1 of the Company&rsquo;s Form 8-K filing on January 11, 2013)</A></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1509261/000091228213000025/ex3_2.htm"><B>3.2</B></A></TD>
    <TD STYLE="text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1509261/000091228213000025/ex3_2.htm">Certificate of Conversion, dated January 10, 2013 (incorporated by reference to Exhibit 3.2 of the Company&rsquo;s Form 8-K filing on January 11, 2013)</A></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1509261/000091228213000025/ex3_3.htm"><B>3.3</B></A></TD>
    <TD STYLE="text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1509261/000091228213000025/ex3_3.htm">Certificate of Incorporation, dated January 10, 2013 (incorporated by reference to Exhibit 3.3 of the Company&rsquo;s Form 8-K filing on January 11, 2013)</A></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1509261/000091228213000025/ex3_4.htm"><B>3.4</B></A></TD>
    <TD STYLE="text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1509261/000091228213000025/ex3_4.htm">Delaware Bylaws, dated January 10, 2013 (incorporated by reference to Exhibit 3.4 of the Company&rsquo;s Form 8-K filing on January 11, 2013)</A></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1509261/000114420414032197/v378391_ex3-5.htm"><B>3.5</B></A></TD>
    <TD STYLE="text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1509261/000114420414032197/v378391_ex3-5.htm">Certificate of Amendment to the Certificate of Incorporation, dated April 30, 2014 (incorporated by reference to Exhibit 3.5 of the Company&rsquo;s Form S-1 filing on May 20, 2014)</A></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1509261/000091228217000211/ex3_1.htm"><B>3.6</B></A></TD>
    <TD STYLE="text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1509261/000091228217000211/ex3_1.htm">Certificate of Amendment to the Certificate of Incorporation, dated November 28, 2017 (incorporated by reference to Exhibit 3.1 of the Company&rsquo;s Form 8-K filing on November 29, 2017)</A></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1509261/000091228215000447/ex3_1.htm"><B>3.7</B></A></TD>
    <TD STYLE="text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1509261/000091228215000447/ex3_1.htm">Certificate of Designation dated December 7, 2015 (incorporated by reference on Exhibit 3.1 of the Company&rsquo;s Form 8-K on December 10, 2016)</A></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1509261/000091228217000211/ex3_2.htm"><B>3.8</B></A></TD>
    <TD STYLE="text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1509261/000091228217000211/ex3_2.htm">Amended and Restated Bylaws, dated November 28, 2017 (incorporated by reference to Exhibit 3.2 of the Company&rsquo;s Form 8-K filing on November 29, 2017)</A></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1509261/000114420417062743/tv480957_ex2-1.htm"><B>3.9</B></A></TD>
    <TD STYLE="text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1509261/000114420417062743/tv480957_ex2-1.htm">Certificate of Ownership and Merger, dated December 6, 2017 (incorporated by reference to Exhibit 2.1 of the Company&rsquo;s Form 8-K filing on December 7, 2017)</A></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1509261/000114420419022478/tv520059_ex3-1.htm"><B>3.10</B></A></TD>
    <TD STYLE="text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1509261/000114420419022478/tv520059_ex3-1.htm">Certificate of Amendment to the Certificate of Incorporation, Dated April 26, 2019 (incorporated by reference to Exhibit 3.1 of the Company&rsquo;s Form 8-K filing on April 30, 2019)</A></TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 15; Value: 18 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0; font-size: 10pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; width: 10%"> <A HREF="http://www.sec.gov/Archives/edgar/data/1509261/000114420419040290/tv527128_ex5-1.htm" STYLE="-sec-extract: exhibit"><B>5.1</B></A> </TD>
    <TD STYLE="text-align: justify; width: 90%"> <A HREF="http://www.sec.gov/Archives/edgar/data/1509261/000114420419040290/tv527128_ex5-1.htm" STYLE="-sec-extract: exhibit">Opinion
    of Dorsey &amp; Whitney LLP **</A> </TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1509261/000091228213000073/ex10_3.htm"><B>10.1</B></A></TD>
    <TD STYLE="text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1509261/000091228213000073/ex10_3.htm">Employment Agreement with Nevan Elam, dated June 18, 2012 (incorporated by reference to the Company&rsquo;s Form 8-K filing on February 6, 2013)</A></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1509261/000091228214000180/ex10_4.htm"><B>10.2</B></A></TD>
    <TD STYLE="text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1509261/000091228214000180/ex10_4.htm">Amended and Restated Employment Agreement with Nevan Elam, dated March 26, 2014 (incorporated by reference to Exhibit 10.4 of the Company&rsquo;s Form 8-K filing on April 1, 2014)</A></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1509261/000091228215000070/ex10_2.htm"><B>10.3</B></A></TD>
    <TD STYLE="text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1509261/000091228215000070/ex10_2.htm">Second Amended and Restated Employment Agreement with Nevan Elam, dated February 23, 2015 (incorporated by reference to the Company&rsquo;s Form 8-K filing on February 24, 2015)</A></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1509261/000091228213000073/ex10_4.htm"><B>10.4</B></A></TD>
    <TD STYLE="text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1509261/000091228213000073/ex10_4.htm">Employment Agreement with Sankaram Mantripragada, dated April 1, 2012 (incorporated by reference to the Company&rsquo;s Form 8-K filing on February 6, 2013)</A></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1509261/000091228214000180/ex10_3.htm"><B>10.5</B></A></TD>
    <TD STYLE="text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1509261/000091228214000180/ex10_3.htm">Amended and Restated Employment Agreement with Sankaram Mantripragada, dated March 26, 2014 (incorporated by reference to Exhibit 10.3 of the Company&rsquo;s Form 8-K filing on April 1, 2014)</A></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1509261/000091228215000070/ex10_3.htm"><B>10.6</B></A></TD>
    <TD STYLE="text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1509261/000091228215000070/ex10_3.htm">Second Amended and Restated Employment Agreement with Sankaram Mantripragada, dated February 23, 2015 (incorporated by reference to the Company&rsquo;s Form 8-K filing on February 24, 2015)</A></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>

<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; width: 10%"><A HREF="http://www.sec.gov/Archives/edgar/data/1509261/000091228213000073/ex10_8.htm"><B>10.7</B></A></TD>
    <TD STYLE="text-align: justify; width: 90%"><A HREF="http://www.sec.gov/Archives/edgar/data/1509261/000091228213000073/ex10_8.htm">Option Agreement with Nevan Elam, dated January 30, 2013 (incorporated by reference to the Company&rsquo;s Form 8-K filing on February 6, 2013)</A></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1509261/000091228213000073/ex10_9.htm"><B>10.8</B></A></TD>
    <TD STYLE="text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1509261/000091228213000073/ex10_9.htm">Option Agreement with Sankaram Mantripragada, dated January 30, 2013 (incorporated by reference to the Company&rsquo;s Form 8-K filing on February 6, 2013)</A></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1509261/000091228214000201/antriabio_def14c-041014.htm"><B>10.9</B></A></TD>
    <TD STYLE="text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1509261/000091228214000201/antriabio_def14c-041014.htm">AntriaBio, Inc. 2014 Stock and Incentive Plan (incorporated by reference to Appendix B to the Company&rsquo;s Definitive Information Statement on Schedule 14C filed on April 10, 2014)</A></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1509261/000091228215000070/ex10_5.htm"><B>10.10</B></A></TD>
    <TD STYLE="text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1509261/000091228215000070/ex10_5.htm">AntriaBio, Inc. 2015 Non Qualified Stock Option Plan (incorporated by reference to the Company&rsquo;s Form 8-K filing on February 24, 2015)</A></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1509261/000091228216000892/ex10_2.htm"><B>10.11</B></A></TD>
    <TD STYLE="text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1509261/000091228216000892/ex10_2.htm">AntriaBio, Inc. 2016 Non Qualified Stock Option Plan (incorporated by reference to the Company&rsquo;s Form &nbsp;8-K filing on November 4, 2016)</A></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1509261/000114420417049237/v474916_ex10-25.htm"><B>10.12</B></A></TD>
    <TD STYLE="text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1509261/000114420417049237/v474916_ex10-25.htm">AntriaBio, Inc. 2016 Non Qualified Stock Option Plan, as Amended (incorporated by reference to the Company&rsquo;s Form 10-K on September 21, 2017)</A></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1509261/000114420416141648/v455882_ex10-1.htm"><B>10.13</B></A></TD>
    <TD STYLE="text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1509261/000114420416141648/v455882_ex10-1.htm">Nevan Elam Refresh Stock Option Agreement (incorporated by reference to the Company&rsquo;s Form 8-K on December 29, 2016)</A></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1509261/000114420416141648/v455882_ex10-2.htm"><B>10.14</B></A></TD>
    <TD STYLE="text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1509261/000114420416141648/v455882_ex10-2.htm">Nevan Elam Prospective Refresh Stock Option Agreement (incorporated by reference to the Company&rsquo;s Form 8-K on December 29, 2016)</A></TD></TR>
</TABLE>

<P STYLE="margin: 0; font-size: 10pt">&nbsp;</P>

<P STYLE="margin: 0; font-size: 10pt"></P>

<!-- Field: Page; Sequence: 17; Value: 18 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0; font-size: 10pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; width: 10%"><A HREF="http://www.sec.gov/Archives/edgar/data/1509261/000114420416141648/v455882_ex10-7.htm"><B>10.15</B></A></TD>
    <TD STYLE="text-align: justify; width: 90%"><A HREF="http://www.sec.gov/Archives/edgar/data/1509261/000114420416141648/v455882_ex10-7.htm">Sankaram Mantripragada Stock Option Agreement (incorporated by reference to the Company&rsquo;s Form 8-K on December 29, 2016)</A></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1509261/000114420417027380/v465723_ex10-1.htm"><B>10.16</B></A></TD>
    <TD STYLE="text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1509261/000114420417027380/v465723_ex10-1.htm">Form of Stock Option Cancellation Agreement (incorporated by reference to the Company&rsquo;s Form 10-Q filing on May 15, 2017)</A></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1509261/000091228217000175/ex10_1.htm"><B>10.17</B></A></TD>
    <TD STYLE="text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1509261/000091228217000175/ex10_1.htm">Development and License Agreement (incorporated by reference to the Company&rsquo;s Form 8-K filing on August 7, 2017)</A></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1509261/000114420417065280/tv482048_ex10-1.htm"><B>10.18</B></A></TD>
    <TD STYLE="text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1509261/000114420417065280/tv482048_ex10-1.htm">Form of Purchase Agreement (incorporated by reference to the Company&rsquo;s Form 8-k filing on December 26, 2017)</A></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1509261/000114420417065280/tv482048_ex10-2.htm"><B>10.19</B></A></TD>
    <TD STYLE="text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1509261/000114420417065280/tv482048_ex10-2.htm">Form of Registration Right Agreement (incorporated by reference to the Company&rsquo;s Form 8-k filing on December 26, 2017)</A></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1509261/000114420418008930/tv484281_ex10-2.htm"><B>10.20</B></A></TD>
    <TD STYLE="text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1509261/000114420418008930/tv484281_ex10-2.htm">Common Stock Purchase Agreement (incorporated by reference to the Company&rsquo;s&nbsp;&nbsp;Form 10-Q filing on February 14, 2018)</A></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>

<TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 10%"><B><A HREF="http://www.sec.gov/Archives/edgar/data/1509261/000114420418008930/tv484281_ex10-1.htm">10.21</A></B></TD>
<TD STYLE="text-align: justify; width: 90%"><A HREF="http://www.sec.gov/Archives/edgar/data/1509261/000114420418008930/tv484281_ex10-1.htm">License Agreement (incorporated by reference to the Company&rsquo;s 10-Q filing on February 14, 2018)</A></TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify"><B>&nbsp;</B></TD>
<TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify"><B><A HREF="http://www.sec.gov/Archives/edgar/data/1509261/000114420418028759/tv492764_ex10-2.htm">10.22</A></B></TD>
<TD STYLE="text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1509261/000114420418028759/tv492764_ex10-2.htm">Amendment No. 1 to License Agreement (incorporated by reference to the Company&rsquo;s 10-Q filing on May 15, 2018)</A></TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify"><B>&nbsp;</B></TD>
<TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify"><B><A HREF="http://www.sec.gov/Archives/edgar/data/1509261/000114420418028759/tv492764_ex10-1.htm">10.23</A></B></TD>
<TD STYLE="text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1509261/000114420418028759/tv492764_ex10-1.htm">Amendment No. 1 to Common Stock Purchase Agreement (incorporated by reference to the Company&rsquo;s 10-Q filing on May 15, 2018)</A></TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify"><B>&nbsp;</B></TD>
<TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify"><B><A HREF="http://www.sec.gov/Archives/edgar/data/1509261/000114420419007974/tv512474_ex10-1.htm">10.24</A></B></TD>
<TD STYLE="text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1509261/000114420419007974/tv512474_ex10-1.htm">Amendment No. 2 to Common Stock Purchase Agreement (incorporated by reference to the Company&rsquo;s 10-Q filing on February 14, 2019)</A></TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify"><B>&nbsp;</B></TD>
<TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify"><B><A HREF="http://www.sec.gov/Archives/edgar/data/1509261/000114420419007974/tv512474_ex10-2.htm">10.25</A></B></TD>
<TD><A HREF="http://www.sec.gov/Archives/edgar/data/1509261/000114420419007974/tv512474_ex10-2.htm">Amendment No. 2 to License Agreement (incorporated by reference to Company&rsquo;s 10-Q filing on February 14, 2019)</A></TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify"><B>&nbsp;</B></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify"><B><A HREF="http://www.sec.gov/Archives/edgar/data/1509261/000114420419007974/tv512474_ex10-3.htm">10.26</A></B></TD>
<TD STYLE="text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1509261/000114420419007974/tv512474_ex10-3.htm">Purchase Agreement for Shares of Series AA Preferred Stock (incorporated by reference to Company&rsquo;s 10-Q filing on February 14, 2019)</A></TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify"><B>&nbsp;</B></TD>
<TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify"><B><A HREF="http://www.sec.gov/Archives/edgar/data/1509261/000114420417049237/v474916_ex10-25.htm">10.27</A></B></TD>
<TD STYLE="text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1509261/000114420417049237/v474916_ex10-25.htm">First Amendment to the 2016 Non-Qualified Stock Option Plan</A></TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify"><B>&nbsp;</B></TD>
<TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify"><B><A HREF="http://www.sec.gov/Archives/edgar/data/1509261/000091228219000086/ex10_1.htm" STYLE="-sec-extract: exhibit">10.28</A></B></TD>
<TD STYLE="text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1509261/000091228219000086/ex10_1.htm" STYLE="-sec-extract: exhibit">Common Stock Purchase Agreement (incorporated by reference to the Company's 8-K filing on July 30, 2019)</A></TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify"><B>&nbsp;</B></TD>
<TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify"><B><A HREF="http://www.sec.gov/Archives/edgar/data/1509261/000091228219000091/ex10_3.htm" STYLE="-sec-extract: exhibit">10.29</A></B></TD>
<TD STYLE="text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1509261/000091228219000091/ex10_3.htm" STYLE="-sec-extract: exhibit">2019 Non Qualified Stock Option Plan (Incorporated by reference to the Company's 8-K filing on August 6, 2019)</A></TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify"><B>&nbsp;</B></TD>
<TD STYLE="text-align: justify">&nbsp;</TD></TR>

<TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 10%"><B><A HREF="http://www.sec.gov/Archives/edgar/data/1509261/000114420418053849/tv503852_ex21-1.htm">21.1</A></B></TD>
<TD STYLE="text-align: justify; width: 90%"><A HREF="http://www.sec.gov/Archives/edgar/data/1509261/000114420418053849/tv503852_ex21-1.htm">Listing of Subsidiaries (incorporated by reference to the Company&rsquo;s Form 10-K filing on October 15, 2018)</A></TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify"><B>&nbsp;</B></TD>
<TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify"> <A HREF="http://www.sec.gov/Archives/edgar/data/1509261/000114420419040290/tv527128_ex23-1.htm" STYLE="-sec-extract: exhibit"><B>23.1</B></A> </TD>
<TD STYLE="text-align: justify"> <A HREF="http://www.sec.gov/Archives/edgar/data/1509261/000114420419040290/tv527128_ex23-1.htm" STYLE="-sec-extract: exhibit">Consent
of EKS&amp;H LLLP **</A> </TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify"><B>&nbsp;</B></TD>
<TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify"> <A HREF="http://www.sec.gov/Archives/edgar/data/1509261/000114420419040290/tv527128_ex5-1.htm" STYLE="-sec-extract: exhibit"><B>23.2</B></A> </TD>
<TD STYLE="text-align: justify"> <A HREF="http://www.sec.gov/Archives/edgar/data/1509261/000114420419040290/tv527128_ex5-1.htm" STYLE="-sec-extract: exhibit">Consent
of Dorsey &amp; Whitney, LLP (included in Exhibit 5.1) **</A> </TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify"><B>&nbsp;</B></TD>
<TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1509261/000114420419040290/tv527128_s-1.htm#signature" STYLE="-sec-extract: exhibit"><B>24.1</B></A></TD>
<TD STYLE="text-align: justify"><A HREF="http://www.sec.gov/Archives/edgar/data/1509261/000114420419040290/tv527128_s-1.htm#signature" STYLE="-sec-extract: exhibit">Power
of Attorney (contained on signature page to the registration statement)</A></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">** Previously filed</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<!-- Field: Page; Sequence: 19; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>img001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img001.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@ - $# P$1  (1 0,1 ?_$ -H   $$ @,! 0
M       '" D* P8!!0L$ @$!  (" P$               4&! <! @,($
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MO)1ZR)N)0X'3,&H&ZMYK*=UM=-+)VE"T\14W:W5O>PBXM7A\)YCN]-*.<Q
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ML80D/D.J5M27@8R.! THWE92/!,%A:M#%5OUW _(2W46+BE9#+:!['R?"6?
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M+;58)ZT3F,9-W-V:9E;!,NB7V\MB.92:?+R,BN5LVGTFZ!5WCDYN0A2D+QX
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M03;-V[=NF5)!!NW1 J2""29 *0A0 I2@    &J>5+B>1U]?IJY -:T,8$8.
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MFIT/*^?Z!^CU>KY/S/(/3ZG)^&Z'/PX\/:X>C2E?03GY"=7DZG(7J<G'DY^
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2Q"G3XJ:\%3OYUGUQ7>C2E?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>img002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" #& D$# 2(  A$! Q$!_\0
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MLA\Q$VD]!\Q'7%3[.FM6D6ZE1M),[#_A>'B[^[IW_@.?_BJ/^%X>+O[NG?\
M@.?_ (JO/KVSN=-O9;.]@>WN86VR12#!4U!D4_94^Q/M:G<](_X7AXN_NZ=_
MX#G_ .*H_P"%X>+O[NG?^ Y_^*KS8D#O5J^L+G39HX;N,1R21+*HW!LHPRIX
M/I1[*GV#VM3N=_\ \+P\7?W=._\  <__ !5'_"\/%W]W3O\ P'/_ ,57$6NA
M:G>0PS06;F*9)7B=B%5UC&7()(SC-9N1ZT>RI]D'M:G<])_X7AXN_NZ=_P"
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M4'&*%3IO9(;E-;GHG_"ZO%G]W3_^_!_^*H_X75XL_NZ?_P!^#_\ %5YUD>M
M(/0T_90["YY=ST7_ (75XL_NZ?\ ]^#_ /%4?\+J\6?W=/\ ^_!_^*KAY=)O
MX-)@U2:UDCLIY#%%*W =@,G ZX]^E4Z7LZ?8.>7<]$_X75XL_NZ?_P!^#_\
M%4?\+J\6?W=/_P"_!_\ BJ\[HI^RAV#GEW/1/^%U>+/[NG_]^#_\51_PNKQ9
M_=T__OP?_BJ\[HH]E#L'/+N>B?\ "ZO%G]W3_P#OP?\ XJC_ (75XL_NZ?\
M]^#_ /%5YW11[*'8.>7<]#;XU^+0I.W3NG_/ _\ Q57M5^,'BBRU*6WB%AL5
M4(W0$GE%)_B]2:\M;[A^E:GB#_D-S_[D7_HM:7LH7V#GEW.Q_P"%U>+/[NG_
M /?@_P#Q5'_"ZO%G]W3_ /OP?_BJYEO!7B-='&J_V7(UD81/YBNA/ED9W;0=
MV,>U96HZ?=:1J$MA?PF"ZAP)(R0=N0".G'0BDH4WLD/FFCN_^%U>+/[NG_\
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M!_\ 18K=\,W&CS^#M:T74]933);JYMY8I'@>4$)NSP@Z\UA'_D5%_P"P@?\
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ML/\ OW1_PKCP=_T+EA_W[KJ**.>7<.6/8Y?_ (5QX._Z%RP_[]T?\*X\'?\
M0N6'_?NNHHHYY=PY8]CF5^'_ (2A#K'X?L564;' C^\N<X/X@?E3?^%<>#?^
MA<L/^_=3>./$4OA7PK<ZQ#;I<20,@$;L5!W,%ZCZUY3_ ,+_ -3_ .@!:?\
M@0W^%:0A5FKQ?XF<YTX.TCU#_A7'@[_H7+#_ +]T?\*X\'?]"Y8?]^Z\O_X7
M_J?_ $ +3_P(;_"C_A?^I_\ 0 M/_ AO\*OV5;^F3[:B>H?\*X\'?]"Y8?\
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M_ AO\*/^%_ZG_P! "T_\"&_PH]C6_IA[:D>I?\*[\'_]"]8?]^Z/^%=^#_\
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MW1_PKOP?_P!"]8?]^Z\M_P"%_P"I_P#0 M/_  (;_"C_ (7_ *G_ - "T_\
M AO\*/8UOZ8>VI'J/_"NO!Y_YEVP_P"_=23> ?"=Q*99M!LGD. 6,?)P,#]
M*\J_X7_J?_0 M/\ P(;_  H_X7_J?_0 M/\ P(;_  H]C6_IA[:D>I?\*[\'
M_P#0O6'_ '[H_P"%=^#_ /H7K#_OW7EO_"_]3_Z %I_X$-_A1_PO_4_^@!:?
M^!#?X4>QK?TP]M2/4O\ A7?@_P#Z%ZP_[]T?\*[\'_\ 0O6'_?NO+?\ A?\
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M ;YB?WA^='F)_>'YTZB@!OF)_>'YT>8G]X?G3J* &^8G]X?G1YB?WA^=.HH
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M!Q@#OD\"@#?HKGK_ ,:Z+IJVAN9IA]I@6X&R%F\N(XP[X'RCGO1J'C71-,U
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MEFF5C& W)*Q8VGVY&31^Z[?@'[WN5/\ A<7C?_H*0_\ @)'_ (4?\+B\;_\
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MMWJ-]?I$EY>W%PD(Q$LTK.$'MD\=!^55J*+(+L***55+,%4%F)P !DD^E,0
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M'[O_ +\)_C1_PS_I_P#T'[O_ +\)_C7L&7_NC\Z,O_='YT>WJ=P]A3['C_\
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MBKM9]GH\%E<)-&\C,B2( Q&,.^\]O6M"@ HHHH **** .#^,7_),]1_WX?\
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2S110 8]S0!BBB@!:*** /__9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
